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INTRODUCTION 
 
 Non alcoholic fatty liver disease is a commonly occurring chronic liver 
disease which includes a spectrum of conditions of varying severity 
characterized by increased deposition of fat in the liver  caused by factors other 
than significant alcohol consumption(1). 
 
 It is the most common chronic liver disease occurring globally 
especially in the developed countries (2). 
 
 The prevalence of the disease is not known exactly, but 9 – 37% of the   
general population is affected by the disease(3,4).            . 
The prevalence and incidence is expected to rise, as the global obesity 
incidence grows in developing countries, with the trend as seen in western 
lifestyle (5,6). 
 
 The disease may affect any age group with the highest rate of incidence 
in the 40 to 49 years. It is the most common disease affecting the liver in the 
pediatric age group. It affects children mainly between  ages 2 to 19(7). 
 
 It comprisesa broadspectrum of pathological conditions involving the 
liver with varying clinical prognoses. The clinically mild end of the spectrum,  
is the simple accumulation of triglycerides inside the hepatocytes (simple fatty 
liver or steatosis)(11).It progresses to the more severe non 
Page 2 of 95 
 
alcoholicsteatohepatitis (NASH). In 10% of cases it may progress to cirrhosis 
in the next 10 years (12). 
 
NAFLD includes the following stages,  
1. Hepatocellular steatosis (simple fatty liver) 
2. Steatohepatitis 
3. Fibrosis   
4. Cirrhosis 
 
 End stage liver failure or even  hepatocellular carcinoma (13,14)constitute 
the most severe end of the spectrum. 
 
 
Figure 1: STAGES OF NAFLD 
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 NAFLD is now recognized as an important component of metabolic 
syndrome and the main underlying pathophysiology of NAFLD, is insulin 
resistance. The metabolic syndrome constitutes a clustering of risk factors like   
atherogenicdyslipidaemia, hypertension (8,9), abdominal obesity  (10) and 
elevated plasma glucose, that makes an individual more prone for developing 
atherosclerotic cardiovascular complications. There is now increasing evidence 
that NAFLD affects other organs too. It affects many extra-hepatic organs and 
regulatory pathways. For example, NAFLD increases the risk for chronic 
kidney disease (CKD)(11) too. 
 
 Liver transplantation is the only treatment for NASH related cirrhosis (12) 
and end stage liver failure.It has been proven that NASH related cirrhosis is the 
second leading cause for liver transplant next to hepatitis C virus related liver 
disease.With increasing industrialization and the global epidemic of NAFLD, 
cirrhosis caused by NASH is likely to become the leading cause of liver 
transplantation by 2030. 
 
 Abdominal imaging by ultrasonography(13), transient elastography 
(fibroscan) (14), computerized tomography and laboratory investigations 
comprising of abnormal liver enzymes cannot distinguish the subjects with non 
alcoholic fatty liver disease with steatohepatitis and subsequent fibrosis. 
 
 The gold standard for confirming the diagnosis, assessing the severity of 
fibrosis, grading the extent of liver damage and to follow up the response to 
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therapyin NAFLD is liver biopsy (15).The disadvantages of liver biopsy, are 
inconvenience to the patient, including pain and bleeding complications, 
sampling error and reducedperformance in obese patients. Sampling error is 
noted with all modes of liver biopsy.This is a tough procedure for the surgeon 
too needing expertise in the technique(16). 
 
 So a simple noninvasive test that accurately differentiates non alcoholic 
fatty liver from non alcoholicsteatohepatitis,as well as determines the severity 
of the disease would be of great clinical use. 
 
 Serum Cytokeratin  18M30 is a biomarker whose levels are 
progressively elevated in the various stages of non alcoholic fatty liver 
disease(17) . 
 
 When hepatocytes accumulate fat, they disrupt the intermediate 
filaments  in the cytoplasm composed of cytokeratin. This results in the 
formation of Mallory bodies .A Mallory body is made up of of abnormally 
phosphorylated and cross linked keratins such as cytokeratin18. 
 
 The hepatocytes with Mallory bodies are more prone for apoptosis. So 
these keratins including cytokeratin 18 are released into the peripheral blood 
during apoptosis (18). So, levels of cytokeratin 18 in the serum are  
progressively elevated in non alcoholic fatty liver  (NAFL) and non 
alcoholicsteatohepatitis (NASH). 
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 The aim of this study is to assess the serum levels of cytokeratin 18M30 
in the various clinicalstages of non alcoholic fatty liver disease. 
 
 Early diagnosis coupled with therapeutic intervention,  can control the 
progression of the disease and prevent the development of the worst 
complications which includes cirrhosis, liver failure and hepatocellular 
carcinoma(19). 
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
 The liver is the largest organ in our body. The nutrientsthat are absorbed 
from the ingested food in the gastrointestinal tract as well as other substances 
including various drugs and bacterial metabolites are processed initially in the 
liver.Thus the liver processes useful metabolites but potentially harmful 
substances taken orally are detoxified in the liver(20). Thereby, the liver 
functions like a gatekeeper. 
 
 The liver contributes a lot in maintaining the biochemical status of the 
body. The metabolic functions performed by the liver are numerous.It plays a 
major role in carbohydrate metabolism. It is one of the sites for 
gluconeogenesis, glycogenesis and glycogen storage (22). Vital biochemical 
compounds are formed from intermediate products of carbohydrate 
metabolism.In the postprandial state the liver plays a crucial role in maintaining 
blood glucose levels within normal limits.It also helps in maintaining normal 
blood glucose levels over short (hours) and long (days to weeks) periods(22). 
 
 The liver plays a vital role in protein metabolism.The synthesis of 
glucose and lipids from the non nitrogenous parts of the amino acids takes 
place in the hepatocytes of the liver. Many of the enzymes used in these 
pathways including alanine aminotransferases and aspartate aminotransferases 
are measured to assess the severity of liver damage in acute and chronic 
diseases of the liver(23). 
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 Lipid metabolism predominantly occurs in the liver.The majority of 
lipoproteins are synthesised in the liver.Excess of carbohydrates and proteins 
are converted into triglycerides and stored in the hepatocytes, which  is the site 
for the synthesis  of cholesterol and phospholipids. 
 
 Thus the liver is an important and altruistic organ (24),coordinating vital 
metabolic processes and maintaining biochemical status and homeostasis of the 
body.When there is a derangement in these metabolic pathways due to any 
cause, which may be environmental or genetic,there occurs an abnormal 
accumulation of the substrates and intermediates in the hepatocytes, altering 
their morphology and function.When it is a chronic cause, there is progressive 
damage to the hepatocytes, leading on to chronic liver disease which may even 
progress to end stage liver failure. 
 
 The commonest of such metabolic derangements isnon alcoholic fatty 
liver which occurs due to a variety of environmental and genetic factors(25). 
 
 It is one of the causes of fatty liver, which occurs when fat deposition in 
the hepatocytes, is more than 5 to 10% of the weight of the liver(26)  when there 
is no history of excessive intake of alcohol.  
 The permissivelevel of alcohol intake varies but can be considered as 
alcohol consumption of not more than 20 grams/ day in males (21 drinks per 
week ) and 10 grams / day (14 drinks per week) in females . 
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 There has been a rapid increase in the incidence as well as prevalence of 
the disease and a  dramatic rise in obesity and type 2 diabetes has been 
observed. The estimated prevalence ranges between 20 and 30% in the general 
population and increasing upto 90% in morbidly obese individuals. Non 
alcoholicsteatohepatitis (NASH), theclinically more severe  form of the 
disease,  is less common, and affects about 2–3% of the general population, and 
up to 74% of the morbidly obese(27). 
 
 NAFLD occurs in about 94% of obese individuals (BMI >30 kg/m2), 
67% of the individuals with overweight (BMI >25 kg/m2), and 25% of 
thenormal  individuals . 
 
 It is closely linkedto type 2 diabetes, and fatty liver occurs in 70% of 
type 2 diabetics screened with ultrasonography(28). It represents the hepatic 
manifestation of   the metabolic syndrome. 
 
 The prevalence of the disease in the pediatric population(29), is 3.2% and 
in obese children it is greatly increased to almost 53%(30).It occurs in all ethnic 
groups. 
 
 It includes a wide range of diseasepathology,ranging from 
simplesteatosis (simple deposition of fat in the hepatocytes, which is mostly 
stable) to non-alcoholic steatohepatitis (cellular ballooning, necro-apoptosis, 
inflammation and fibrosis, which is more severe) and progresses to 
cirrhosis(31).Cirrhosis is clinically the most severe end of the spectrum. 
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 In a minority of cases it may worsen resulting in end stage liver failure 
or hepatocellular carcinoma (2 to 3%).  Due to the rapid increase in 
prevalence,NAFLD related cirrhosis ( cryptogenic cirrhosis)  has become 
acommon indication for liver transplantation. 
Historical perspective 
 Fatty liver was firstdescribed in the nineteenth century by the scientist 
Virchow. Heexplained the different classes of fatty liver.He also described the 
gross appearance of fatty liver including the yellowish discoloration,change in 
shape due to increased size and increased firmness of the liver.The globules of 
fat were proved to be inside the hepatocytes. The word “fatty liver” was coined 
by Ludwig(32). 
 
 Later on, in the 1870s Morgan explained a strong association between 
fatty liver and obesity and also with over-eating. 
 
 Several years later Zelman confirmed liver fibrosis and cirrhosis in 
obese patients without alcohol abuse. In 1970s, fatty liver was noted in patients 
who underwent intestinal bypass for treatment of morbid obesity. 
 
Epidemiology 
 NAFLD is the commonestliver disease globally, with a worldwide 
prevalence of 6 – 33%. Whereas, in western countries it is about 20 -30%(33). 
 
 In the Asian continent, the prevalence varies between 12 - 24 % ( 34 ). 
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 The occurrence of NAFLD in Asian countries is much lesser than the 
western countries but, of late, ithas greatly  increased in Asia too, due to the 
gradual increase in obesity, type 2 diabetes and metabolic syndrome  in these 
regions.This is mainly due to the change in lifestyle and industrialization. 
 
 The prevalence is estimated to be around 5 - 28% in the Indian 
population( 35 ). 
 
Genetic basis 
 NAFLD is a complex disease trait in which minor inter-patient genetic 
variations act together with environmental factors to determine disease 
phenotype and its progression.  These genetic variations that 
determinesteatosis, are being studied and mapped by GENOME WIDE 
ASSOCIATION STUDIES (GWAS)(36). 
 
 Several non-synonymous sequence variations were studied and  a 
missense mutation  [Ile148→Met148 (I148M)]  was located in a PATATIN-
like PHOSPHOLIPASE domain-containing, i.e., PNPLA 3 gene 
(PNPLA3)(HCNG: 18590) (37).PNPLA3mutations are greatly expressed in 
adipose tissue and liver, and their actions are regulated by insulin through a 
signaling cascade which is greatly increased with feeds(38). 
 
 Additionally, the PNPLA3 gene also,causes difference in the prevalence 
of fatty liver disease between various ethnic groups(39). The prevalence of 
NAFLD is much higher in the Hispanics(Whites) when compared to the Black 
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Americans. Most probably, this may also be the reason for familial clustering 
of NAFLD. The frequency of PNPLA3 gene was much higher in NAFLD 
patients, when compared to normal individuals,with a 3.3- fold increased 
risk(40).  
 The rs738409 single nuclear polymorphism,  influenced  both the 
presence of NASH and the severity of fibrosis in NAFLD patients, with 
histological evaluation of liver damage, independent of obesity and 
diabetes(41,42) . 
 
 Five new genetic variants were found to be associated with progressive 
inflammation and fibrosis in NAFLD  : 
 
1. A variant in the FDFT1 (farnesyldiphosphatefarnesyltransferase 1, HGNCI 
3629) was correlated with NAFLD(43). 
2. The collagen gene COL13A1 (collagen, type XIII, alpha 1, HGNC 2190) 
was associated with lobular inflammation(43). 
3. A single nucleotide polymorphism near the PDGFA gene (platelet-
derivedgrowth factor alpha polypeptide, HGNC 8799); 
4. The LTBP3 (LATENT TRANSFORMING GROWTH FACTOR BETA-
BINDING PROTEIN 3, HGNC 6716), and  the 
5. EFCAB4B (EF-hand calcium binding domain 4B, HGNC: 28657). 
 
 Genomewise association studies,  identified four other SNPs which 
positively correlated with  degree of steatosis and  progression of NAFLD. 
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These were 
1. neurocan  (NCAN, SNP rs2228603),(44) 
2. protein phosphatase 1, regulatory (inhibitor) subunit 3B (PP1R3B, SNP 
rs4240624). 
3. glucokinase regulator (GCKR, SNP rs780094) and 
4. lysphospholipase like 1 (LYPLAL1, SNP rs12137855). 
 
 NCANregulates cell to cell adhesion and lipoprotein metabolism, and 
closely linked  with biopsy provensteatosis. 
 
 GCKR is one of the regulatory factors in the metabolism of glucose. 
 
 LYPLAL1 coordinates the actions ofPNPLA3 protein, in the breakdown 
of the  triglycerides. 
 
 Both GCKR and LYPLAL1 were also proved to be closely linked with 
biopsy proven,lobular inflammation of the hepatocytes  and fibrosis. 
 
 The SNP rs2645424 on chromosome 8, in the gene encoding 
FARNESYL DIPHOSPHATE FARNESYL TRANSFERASE 1 (FDFT1), an 
enzyme involved   cholesterolbiosynthesis, was found to be associated with 
progression of NAFLD. 
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Figure2 :Genetic factors in NASH 
 
Etiological conditions associated with non alcoholic fatty livermetabolic 
factors  
 Metabolic syndrome: 
1. Type 2 diabetes mellitus,associated with insulin resistance. 
2. Obesity (especially truncal/central obesity). 
3. Hyperlipidemia (especially hyper triglyceridemia). 
4. Hypertension. 
5. Polycystic ovarian disease. 
Genetic / metabolic conditions  
1. Lipodystrophies 
2. Wilson’s disease 
3. Abetalipoproteinemia 
4.  Galactosemia 
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5. Heriditary fructose intolerance 
6. Systemic carnitine deficiency 
7.Tyrosinemia 
 
Toxin- associated steatohepatitis(45) 
 Drugs 
1. Methotrexate 
2. Amiodarone 
3. Tamoxifen 
4. Nucleoside analogues 
 Occupation associated toxins 
1. Carbon tetrachloride 
2. Ethyl bromide 
3. Petrochemicals 
4. Vinyl chloride 
 Malnutrition states and parenteral nutrition 
1. Total parenteral nutrition 
2. Kwashiorkor 
3. Celiac disease. 
 Miscellaneous conditions 
1.Inflammatory bowel disease 
2.Jejunal diverticulosis with bacterial overgrowth 
3. Gastric and jejunoileal bypass 
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Type 2 diabetes mellitus and insulin resistance in NAFLD 
Insulin resistance is the core mechanism in NAFLD. 
Hyperinsulinemia and insulin resistance can be noticed by the action of insulin 
on the target tissues like adipose tissue (continual lipolysis and reduced uptake 
of free fatty acids), muscle (diminished glucose release) and liver (reduced 
glycogenesis and glucose release ).The development  of  diabetes mellitus is 
dependent  on  vitality of pancreatic islet cells  but, it has been proved 
thatsteatosis mostly occurs, before  development of diabetes in susceptible 
individuals. 
            Ethnicity significantly influences these associations. Previous studies 
prove that the fattyinfiltration of the liver  occurs in three fourths of type 2 
diabetes mellitus patients (46).Pathological changes in the liver worsen with 
deranged glucose metabolism and,diabetes mellitus in NAFLD doubles the risk 
for cirrhosis. 
 
Obesity and NAFLD 
Non alcoholic fatty liver is four to six times common in obese individualswhen 
compared to normal individuals by ultrasonography and abnormal liver 
enzymes(47).About 30% had significant fibrosis and 10% had cirrhosis.But 
ethnic factors significantly affect the relationship between obesity and NAFLD. 
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Metabolic syndrome and NAFLD 
 Obesity and steatosis, are major risk factors for metabolic syndrome 
having the common underlying mechanism of insulin resistance and 
lipotoxicity. There is an increased prevalence of about 60% of NAFLD in 
metabolic syndrome(48). 
 
NASH in other liver diseases 
        Occult haemochromatosis and iron overload(49), is an important additional  
factor in the development of NASH. Moreover,hyperferritinemia is more 
closely associated with insulin resistance rather than iron overload and can be 
reversed by weight reduction. 
 
 Recently hepatic steatosis is also implicated as a major risk factor in the 
development of  primary biliary cirrhosis. 
 
Classification of NAFLD 
Class 1:Simple fatty liver or simple steatosis (without inflammation or fibrosis) 
Class 2:Steatosis with lobular inflammation without fibrosis or ballooned cell -  
Non alcoholicsteatohepatitis (NASH) 
Class 3:Steatosis associated with inflammation/fibrosis of different degrees 
Class 4:Steatosis associated with inflammation/fibrosis with ballooned cells 
containing MALLORY BODIES. 
Class 1 and 2 are clinically mildconditions (50) 
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Pathogenesis 
 The pathogenesis of NAFLD can be described based on the “two hit 
hypothesis”. 
          The ‘first hit’, which has triglyceride deposition in the hepatocytes,  
causes steatosis .This makes the liver more prone to injury, caused by the 
following mediators so called “second hits” (51,52) 
 Inflammatory Cytokines, 
 Adipokines,  
 Mitochondrial dysfunction  
 Oxidative stress 
 
 These results, in cellular ballooning,steatohepatitis,cell death, fibrosis 
and cirrhosis.But free fatty acidstoo, have a direct role in promoting liver 
injury(53). 
 
 
Figure 3:PATHOGENESIS OF NAFLD – THE TWO HIT HYPOTHESIS 
Steatosis 
Page 18 of 95 
 
Steatosis occurs when fat deposition in the liver is greater than 5 to 10% of the 
weight of the liver (54)..Excessive accumulation of  fat in the liver parenchyma, 
occurs due to a derangement in the balance between supply,synthesis, 
consumption and usage of triglycerides. 
 
             The following are the sources of the lipids that contribute to the 
development of fatty liver  
1. The uptake of non esterifiedfree fatty acids (NEFA) from the plasma 
which comes from lipolysis of the adipose tissue.  
2. The newly synthesized fatty acids in the liver through de novo 
lipogenesis (DNL) from carbohydrate precursor. 
3. Dietary fatty acids which reach the liver through uptake of intestinal 
chylomicrons. 
 Tracer studies done in NASH patients, who are obese,showed  that 60% 
of triglycerides in the liver come from free fatty acids, 25% from de novo 
lipogenesis, and 15% from  diet (55). 
 
The disposal and usage of fatty acids proceeds in many ways; 
1. esterification to triglycerides and incorporation into  lipid dropletsin the 
cytoplasm. 
2. lipoproteins such as VLDL, are formed and exported out of the liver. 
3. oxidation of fatty acids through β oxidation in mitochondria. 
4. synthesis of membrane phospholipids. 
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 These pathways are regulated by energy homeostasis influenced by 
Peroxisome Proliferators Activated Receptors (PPAR) activity and the 
adrenergic nervous system. 
             The transcription factors consisting ofSterol Regulatory Element 
Binding Protein (SREBP)(56) regulated by insulin,  and Carbohydrate Response 
Element Binding Protein(CREBP)(57), regulated by glucose levels play an 
important role in lipid metabolism. SREBP and CREBP,promote  transcription 
of the enzymes regulating fatty acid synthesis, esterification into triglycerides 
in lipid droplets and thus promoting lipogenesis. 
 
Fructose is a key player in NAFLD 
 Fructose plays a pivotal role in the pathogenesis of NAFLD(58).The 
composition of the food we eat, greatly influences  deposition of hepatic fat. 
Carbohydrates,especially fructose,plays  a key role in the development of 
steatosis. Increased  fructose intake is strongly associated with adverse changes 
in lipid profiles. 
 
 High Fructose Corn Syrup (HFCS) has become a common constituent of 
our food items, from the 1970s. Soft drinks and sweetened beverages contain 
high quantities of fructose.They contain 55% fructose,41% glucose and 4% 
complex polysaccharides(60,61). 
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       Fast food or “CAFETERIA” style food, are rich in high saturated fats, 
cholesterol and fructose. These fast food diet, promotes a gene expression that 
causes hepatic fibrosis, endoplasmic reticulum stress and lipoapoptosis. 
 
 The absorbed fructose from the intestinesis almost entirely extracted by 
the liver, amounting to 50 to 70% of the fructose reaching the liver(62).The 
anatomicallocation of the liver has gained an access to be in a key buffering 
position for absorption of amino acids and carbohydrates.Fructose extraction 
and metabolism, is significantly increased in the liver when compared to 
glucose, due to the extensive amount of fructokinasein the liver, which 
phosphorylates fructose. 
 
 The following are the mechanisms by which fructose induces hepatic 
steatosis.  
 Increased fructose supply thrust stresson the hepatocytes, due to the 
activation of c-Jun-N terminal kinases and reduced hepatic insulin 
signaling leading on to insulin resistance(62,64).  
   In fructose intake,dietary carbons  are delivered to the liver in a state  
that is  primed already to enter de novo lipogenesis. 
 Fructose is phosphorylated at carbon 1, rather than carbon 6, which is 
converted to glyceraldehydes 3 phosphate which is the substratefor de 
novo lipogenesis. 
 Fructose may prevent suppression of GHRELIN secretion(63) causing 
defectivesatiety mechanisms. 
Page 21 of 95 
 
 When taken in large amounts,fructose can stress the liver by depleting 
hepatic energy supplies. After fructose injection,patients with NASH 
and normal individuals showed similar exhaustion of hepatic ATP 
levels, but the recovery of ATP levels to normal levels was much slower 
in NASH patients when compared to healthy subjects(63). 
 
 Previous studies which compared glucose and fructose metabolism in 
post-absorptive humans over short intervals have proved that fructose is 
metabolized much faster than glucose. 
 
 So by reducing fructose intake by avoiding fast food and soft drinks 
hepatic steatosis and NASH can be controlled. 
 
Lipid composition (lipodomics) in NAFLD 
 Diacylglycerol Acyltransferase-1 (DGAT) is the enzyme responsible for 
esterification of NEFA into triglycerides in lipid droplets(65,66). LIPODOMIC 
studies show an increasein the triacylglyceride to diacylglyceride ratio in 
NASH, compared to NAFL. So,triacylglycerides are elevated in  severe 
NASH(67.68). 
 
             The ratio of n6:n3 polyunsaturated fattyacid  (PUFA) is altered,(69.70) 
and the arachidonic acid levels are almost depleted in NASH. Free fatty acids 
were not different, but phosphatidylcholine was decreased in simple steatosis 
and NASH, while the free cholesterol to phosphatidylcholine ratio was 
increased. Ceramide, a toxic lipid intermediate, is found to be increased in 
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obesity associated NAFL, when compared with lean individuals presenting 
with fatty liver. 
 
 
Figure 4 :LIPID HOMEOSTASIS IN NAFLD 
 
Lipid peroxidation 
 Lipid peroxidation is the important feature that differentiates simple 
fatty liver from NASH.This is proved by the accumulation of oxidative by-
products like malondialdehyde (MDA)(71),4-hydroxynonenal, nitrotyrosine, 8 
hydroxydeoxyguanine, and systemic accumulation of adducts of oxidized 
phospholipids and 11 hydroxyeicosatetraenoic acid (11-HETE) (72) , which is a 
byproduct of arachidonic acid oxidative injury. 
 
 Lipid peroxidation  occurs by branching chain reaction attack  on 
unsaturated fatty acids that results in the production of a lipid hydroperoxide 
and another free radical.This is initiated mainly by superoxide radicals which 
are produced from mitochondrial oxidative phosphorylation in the electron 
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transport chain.Superoxide dismutase metabolises  superoxide radical  to 
hydrogen peroxide.This is converted to hydroxyl radicals (OH- ) in the presence 
of ferrous ions (Fe 2+) .This is called Fenton’s or Haber-Weiss reaction. The 
hydroxyl radicals have a catalytic role in the peroxidation of fatty acids, which 
cause alteration and damage to cellular proteins, membranes and DNA.  
 
 Theoxidation of the phospholipid monolayer of lipid droplets composed 
of  ,adipose differentiation related  protein (ADRP), PERILIPIN  AND  TAIL 
interacting  protein ( collectively called PAT proteins) and constituent proteins 
of the endoplasmic reticulum are associated  with  cellular ballooning of 
hepatocytes,defective disposal of fatty acids and hepatic insulin resistance.The 
velocity of these biochemical  reactions in the body, whether indays, hours , 
minutes or seconds or longer is not known. 
 
VLDL lipidation andlipophagy 
 The fat droplets aresynthesized at the site of fatty acid acyl transferases 
in the endoplasmic reticulum in association with the cytoskeleton.Lipid 
droplets are associated with lipoprotein like proteins called PAT proteins which 
regulate lipase activity.These PAT proteins and are  regulated by 
PPARγagonists.The growth  of these proteins occurs principally by fusion.The 
triglycerides required for VLDL synthesis comes from the lipid droplets and 
this is activated by MTTP enzyme at the endoplasmic reticulum.Since  
PATprotein expression  is altered by oxidative injury to the droplet surface ,the 
secretion   and fusion  of these droplets are disturbed in NASH . 
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 Autodigestionof lipid droplets (lipophagy) occurs by formation of 
autophagosome (fusion with lysosome) is an important compensatory 
mechanism. This leads to alterations in the permeability of the autophagosome 
which is mediated by free fatty acids and triggers apoptosis and cell death. 
 
 
Figure 5  MOLECULAR MECHANISMS AND INFLAMMATORY 
CYTOKINES IN NASH 
 
Endoplasmic reticulum dysfunction 
 Accumulation of lipid droplets results in   formation of “Apo – B 
crescents” (rich in cholesterol) at sites in the endoplasmic reticulum(73).This 
causes  stress and altered function of  endoplasmic reticulum.This endoplasmic 
reticulum stress  activates inflammatory mediators like  nuclear factor κB (NF- 
Κb ), interleukin 8 and c-jun N- terminal kinase (JNK) .So defective interaction 
of Apo B100  with lipid droplets at the endoplasmic reticulum produces an 
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association of oxidative stress with the endoplasmic stress reaction, lipid 
droplet accumulation,defective VLDL secretion and activation of pro-
inflammatory pathways. 
 
Dysfunction of mitochondria and ATP homeostasis 
 Steatosisis  stronglyassociated with reduced ATP levels . This was first 
describedabout 50 years ago .  P31 magnetic resonance spectroscopic studies 
have proved this recently .The history of mitochondrial evolution has placed  it 
centrally in key  pathways of synthesis of fatty acids and oxidation and 
apoptotic signaling. 
 
Morphological changes in the mitochondria in NASH are  
1. enlargement  of the mitochondria 
2. development of  mitochondrial paracrystalline inclusions(74,75) 
which represent phospholipid phase transition. 
 
 This is due to defective electron transport chain(76) together with 
uncoupling of protein. The products of lipid peroxidation cause activation of 
mitochondrial UNCOUPLING PROTEIN (UCP – 2).UCP – 2 causes reduction 
in reactive oxygen species (ROS) by reducing ATP synthesis in the 
mitochondria.This results in ATP depletion under stress(77). 
 
 The increase in cholesterol content in mitochondria causesaltered 
mitochondrial permeability.This results in release of cytochrome C and triggers 
apoptosis(78). 
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Apoptotic cell death causing fibrosis 
 Apoptosis is programmed cell death that occurs by highly organized 
cellular and nuclear fragmentation. 
 
 During this process, cells are split up into fragments of small membrane-
bound apoptotic bodies. These are digested and removed  by phagocytosis.  
 
Apoptosis can occur by two main pathways (79): 
 extrinsic pathway -  mediated by death receptors present on the  
surface of the cell 
 the intrinsic pathway - is organelle based.  
 
 The extrinsic pathway is initiated by apoptotic death receptors which 
includes Fas, TNF-R1 and TNF related apoptosis inducing ligand 
receptors(TRAIL).When activated, these receptors activate intracellular 
cascade systems which in turn stimulate proteolytic enzymes, mainly the 
caspases and cause cell death. 
 
 In the intrinsic pathway, many intracellular organelles stimulate 
apoptosis.Nuclear DNA damage,altered lysosomal permeability, endoplasmic 
reticulum stress,  and mitochondrial dysfunction can trigger apoptosis.  
 
 Lysosomes release cathepsinB , a protease during TNF-α signaling , 
which causes mitochondrial dysfunction and cytochrome C is released(80,81). 
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 Increase in TRAIL content in the cytoplasm increases lysosomal 
permeability and release of cathepsin B into the cytoplasm from the 
lysosomes(82,83). 
 
 In hepatocytes, mitochondrial dysfunction plays a crucial role by 
stimulatingthe apoptotic pathways and both the pathways are integrated into a 
common one . 
 
 Mitochondrial dysfunction releases many pro-apoptotic factors  into the 
cytoplasm .This includes cytochrome c, which together with apoptotic-protein 
activation factor-1 (Apaf-1) and caspase 9, forms an activation complex, viz., 
the apoptosome. 
 
 This activation complex stimulates  the effector caspases 3, 6 and 7 
which complete the process of apoptosis and cause the final changes(84).  The 
Bcl-2 family of proteins consisting of pro-apoptotic (Bax,Bak) and anti-
apoptotic (Bcl-2, Bcl-xL)(85,86) regulate the mitochondrial actions of apoptosis. 
 
 Matrix metalloproteinase (MMPS) are also secreted by the activated 
HSCS which also promote hepatic fibrogenesis  and TNF- α  is released into 
the peripheral circulation. Animals experiments done in mice showed that 
diminished  action of MMPS decreased liver injury, magnitude of apoptosis 
and fibrosis. 
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Lipotoxicity stimulates apoptosis 
 Numerous studies have proved that free cholesterol and saturated fatty 
acids(SFAS)  which are critical in causing  lipotoxocity  also induce apoptotic 
signaling . Fatty acid transport proteins (FATPs) passively transport the FFAS 
across the hepatocyte membrane. Bechman et al explained that “FAT CD 36 / 
Fatty acid translocase was increased in NASH together with serum FFA  and  
mediators of apoptosis. ” 
 
 TNF- α   is an important inflammatory cytokine that is proapoptotic.  
Mari and his colleagues demonstrated that, excess free cholesterol made the 
hepotocytes sensitive to TNF-α, with subsequent apoptosis and progression to 
steatohepatitis. 
 
 Experimental studies prove that a cholesterol rich diet caused TNF- α 
stimulated cytochrome c release. Mitochondrial glutathione was also reduced. 
 
 TRAIL also promotes apoptosis. Malhi et al explained that FFAS made 
hepotocyies sensitive to TRAIL mediated apoptosis. 
             A combination of apoptotic signaling and focal necrosis results in 
necroapoptosis , which causes cell death. 
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The various responses to cell death include  
 Cell repair,  
 Inflammation,  
 Regeneration,  
 Fibrosis(87) 
 
 Among these responses, hepatic fibrosis is potentially the  most 
deleterious(88), since progressive fibrosis may cause cirrhosis associated with 
subsequent grave complications of portal hypertension, liver failure and 
hepatocellular carcinoma. 
 
 Experiments in animalsand human studies have proved that, there is  a 
link between hepatocyte apoptosis and liver fibrogenesis(89). In animal 
studies,the reductionin the magnitude of hepatocyte apoptosis also produces 
reduction infibrogenesis(90,91). 
 
 The hepatic stellate cells(HSC) engulf the apoptotic bodies 
whichstimulates the fibrogenic potential of these cells(92).So the amount of 
hepatocyte apoptosis correlates with increasing magnitudeof  fibrosis . Recent 
studies also prove that the nuclear DNA released from apoptotic cells also 
stimulate HSC cells and subsequent fibrogenesis(93). 
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Figure 6 :FIBROGENESIS IN NAFLD 
 
In NAFLD   the mechanism of apoptosis in hepatocytes  is as follows: 
Excessive free fatty acids (due to reduced fatty acid binding protein) 
↓ 
Alters  autophagosome permeability 
↓ 
Facilitates  cathepsinB (lysosomal proteases) release 
↓ 
Changes in  permeability of mitochondria 
↓ 
 Release of cytochrome C andactivation of pro-apoptotic caspases 
(caspases 3,6 and 7) 
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 Caspase 3 particularly causes disintegration of keratin 18 present in the 
intermediate filaments  resulting in the formation of Mallory –Denk bodies and 
release of  fragments of keratin 18  into the blood(94). 
 
 Previous studies using the TUNEL assay (terminal 
deoxynucleotidyltransferase-Tdt mediated dUTP nick end labelling technique) 
and immunohistochemical detection of caspase 3 in a large group of  NAFLD 
patients, confirmed that hepatocyte apoptosis is the key pathological 
characteristic of human NAFLD(95). 
 
 The  amountof hepatocyte apoptosis correlates with severity of fibrosis, 
AST/ALT ratio and degree of inflammation. 
 Apoptotic pathways are diffusely activated due to depletion of ATP , 
accumulation of lipid droplets and  injury to the cytoskeleton,  which contribute 
to hepatocyte ballooning. 
 
Ballooned cells 
 Ballooning of the hepatocytes is the characteristic  histological finding 
in simple steatosis and NASH (96,97).This occurs due to accumulation of fat, 
pushing the nucleus to the periphery.Ballooning is increase in cell size about 
1.5 to 2 times the normal size on biopsy sections (normal diameter is 30 μm) 
with rarified cytoplasm(98). 
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Figure 7: BALLOONED AND LIPID LADEN CELLS IN NAFL ON 
HISTOPATHOLOGICAL EXAMINATION 
 
 Ballooning due to lipid accumulation  injures the cytoskeleton and 
intermediate filaments,  forming Mallory-Denk bodies . Rupture of 
intermediate filaments releases fragments of cytokeratin 18 into the peripheral 
blood(99,100). Ballooning of hepatocytes correlates with increasing fibrosis. 
Insulin resistance causing inflammatory changes 
 Insulin   resistance is the main hallmark of NAFLD, whichoccurs  in 
most of NAFLD patients, and is responsible for  development of the disease . 
 
 In normal subjects, insulin binding to its receptor phosphorylates  
insulin receptor substrates (IRS)-1, 2, 3 and 4, which results in propagation of  
the insulin signal.Phosphorylation of IRS-1 and 2  activates intracellular PI3K 
(phosphoinositide 3-kinase) and AKT/PKB (protein kinase B) pathways.These 
reactions  are mainly responsible for the  metabolic actions of insulin.The 
stimulation of AKT/PKB, translocatevesicles containing (glucose transporter 4) 
GLUT4 to the plasma membrane.Thispromotes glucose uptake(101). 
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 Moreover theupregulation of forkhead box containing protein O 
(FOXO) transcription factor activity, facilitates the expression of important 
lipogenic genes with an associated reduction in glucogenic gene expression(102). 
 
 In insulin resistance,phosphorylation in the IRS changes from tyrosine 
phosphorylation to serine phosphorylation.resulting in reduced insulin action in 
the reactions mediated by phosphatidylinositol 3-kinase(103), AKT/PKB 
pathway and mitogenic pathways (mediated by Ras and mitogen activated 
protein).Inflammatory changes occur in theadipose tissue, due to endoplasmic 
reticulum stress and stimulation of Jun amino-terminal kinases (JNK).This 
causes the release of numerouscytokines, which changes  tyrosine 
phosphorylationto serine phosphorylation. 
 
 Most of the biochemical abnormalities in NAFLD are due to 
interference with  insulin signaling which results in insulin resistance. The 
factors which interfere with insulin signaling are free fatty acids, nuclear factor 
kappa B (NF-kB), ceramide, Jun N-terminal kinase 1 (JNK1), suppressors of 
cytokine signaling (SOCS) and cytochrome CYP2E. 
 
 Accumulation of intermediates of lipid metabolism likediacylglycerol 
(DAG) also reduces insulin signaling by protein kinase C (PKC) mediated 
mechanism. The above processes are also seen in skeletal muscles, which lead 
on to a systemicstate of insulin resistance(105,106). 
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Inflammatory cytokines in nonalcoholic  steatohepatitis 
 Cytokines have a key role in the pathogenesis of NAFLD by facilitating 
hepatic inflammation, apoptosis and fibrogenesis. 
 
 TNF-α, an inflammatory mediator, is secreted by hepatocytes and 
Kupffer cells Previous studies have  proved that,thereis a correlation between 
TNF-α expression and insulin resistance in NASH.  Adipose tissue is a 
predominant site of obesity – mediated inflammation, facilitated by TNF-α 
expression, which causes inflammatory changes and insulin resistance. 
Elevated TNF-α levels were noted in obeseindividuals compared to lean 
individuals, and were positively correlated to insulin resistance(106).Circulating 
TNF-α levels was found to rise with increasing degrees of fibrosis in NASH. 
 
 In the liver, transforming growth factor β1 (TGF-β1) is secreted by  
stellate cells, Kupffer cells and epithelial cells. TGF-β1 facilitates hepatic 
fibrogenesis(107)by: 
 stimulating  stellate cells  causing release of extracellular matrix pro-
teins.  
 transformation of resting stellate cells to myofibroblasts. 
 Polymorphisms involving TGF-β1 are linked to severe hepatic fibrosis 
in  NAFLD  patients with obesity. 
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Lipid homeostasis in NAFLD       
 Dysregulation of fat metabolism in NAFLD is characterized by 
increased production of very-lowdensity lipoproteins (VLDL), the key 
lipoprotein of the metabolic syndrome. Insulin resistance increases VLDL 
secretion in order to maintain hepatic lipid homeostasis. The small, dense LDL 
(sdLDL) which is highly  atherogenic,  is increased in  NAFLD. 
 
NAFLD associated dyslipidemic profile is  characterized by: 
                   Increased plasma VLDL, 
                   Increased plasma  LDL, and  
Decreased  HDL . 
 
 
 Many studies have documented the association between fatty liver and 
small dense LDL (sdLDL) concentration .The sdLDL are formed after removal 
of triglycerides from LDL. Since there is accelerated production and release 
triglyceride-rich VLDL into the plasma ,sd LDL,  also get accumulated more.   
 
These actions are facilitated by two enzymes. 
            First, cholesteryl ester transfer protein (CETP) promotes the triglyceride 
transfer from VLDL to LDL and cholesteryl esters from LDL to VLDL.  
 
            Secondly, hepatic lipase promotes lipolysis of triglyceride-rich LDL 
forming sdLDL.  
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            So, CETP remodels VLDL in circulation, increasing its cholesterol 
content  and also in conjuction with hepatic lipase,  facilitates the sdLDL 
production(108).The mechanism of CETP is greatly increased in NAFLD . 
 
 LDL receptor exhibits a lesser attraction for smaller particles and so 
such sdLDL remain in the circulation for a long time. 
 
 Hyperlipidemia can also be caused by increased levels of apolipoprotein 
C-III (APOC-III), which inhibits lipoprotein lipase. APOC-
IIIpolymorphismsalso cause NAFLD in humans. 
 
 Compared to simple steatosis, in steatohepatitis there is dysfunctional 
VLDL production and release.Fujita et al.compared  serum lipoprotein levels 
between simple steatosis and NASH.  Lipid profiles were same in the two 
groups; but the production and secretion of VLDLwere defective  in NASH(109). 
 
 The defective hepatic VLDL export causes triglycerides to accumulate 
in the liver.MTTP is required  for VLDL synthesis in the liver .  MTTP 
polymorphisms causediminishedactivity of matrix metalloproteinases(MMPs)  
and secretion of VLDL  which  leads  to greater  triglyceride accumulation in 
the hepatocytes.  This promotes development ofNASH . Also a fat rich diet was 
found to stimulate the methylation of MTTP and subsesequently lowers its 
mRNA level(110). The postabsorptive phase also causes oxidative stress .  
Oxidized LDL stimulate HSCs that promote fibrogenesis in NASH.  
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 Sortilins, intracellular sorting receptors for apolipoprotein B 100 (apo-B 
100),attribute an important role in lipoprotein metabolism. Genome-wide 
association studies showed that sortilin 1 (Sort 1) gene was associated with 
metabolism of LDL. Numerous studies prove thatsortilin 1 is associated with 
hepatic metabolism oflipoproteins containing apo-B, but the exact mechanism 
is not clear. 
 
 Kjolby et al. confirmed that, “Sort 1 reacts with Apo-B 100 in the Golgi 
apparatus and promotesthe synthesis and export of VLDL lipoproteins, thus 
maintaining plasma LDL levels” (111). They confirmed that over-expression 
ofSort 1promotesrelease of lipoproteins from the liver and elevated plasma 
LDL levels. Plasma LDL concentration, (the lipoprotein with highest 
cholesterol content in humans), is regulated by rate of synthesis and clearance 
by LDL receptors. 
 
 Fatty acid synthase (FAS) has a catalytic role in the final step ofde novo 
synthesis of fatty acidsand determines  the maximal hepatic capacity to 
synthesize fatty acids. The expression of FAS mRNA in human liver is 
increased in hepatic steatosis. 
 
 Liver X receptors(LXRs) are nuclear receptors in hepatocytes  that have 
a criticalrole in the lipid related genesis of NAFLD(112,113). 
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The various actions of LXR are: 
 LXRs were found to serve as steroid  sensors that regulate cholesterol 
metabolism(114 ,115) 
 LXR stimulation promotes hepatic lipid accumulation and induces the 
synthesis as well as the export of VLDL particles from the liver.  
 LXR stimulates SREBP-1c, the chief  transcriptional regulator of  de 
novo synthesis of fatty acid synthesis (116). 
 LXR regulates insulin dependent stimulation  of SREBP-1c . 
  LXR can alsofacilitatelipogenesis by SREBP-1c independent 
mechanisms(117). 
 LXRs can stimulate other transcriptional factors like ChREBP involved 
in lipogenesis(118). 
 Theyinducethe CD-36 expression, fatty acid transporter, and scavenger 
receptor, which is  another pathway by which LXR facilitates 
development of steatosis(119).  
 They inhibit LDLR-mediated cholesterol uptake by stimulatingthe 
expression of inducible degrader of the LDLR (IDOL)(120). IDOL 
promotes the ubiquitinization of LDLR anddegrades it. 
 
Endotoxins and signals derived from the gut 
 Microbes in the gut have a role in NAFLD and NASH, HCC and 
atherosclerotic  vascular disease, diabetes and other conditions.Endotoxins or 
lipopolysaccharides (LPS) secreted by the gut microbes  may reach the liver 
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through the portal vein crossing the intestinal barrier. Patients with histological  
evidence of NAFLD have increased intestinal permeability with disrupted 
intercellular tight junctions in the intestine(121). These changes are associated 
with bacterial overgrowth in the small intestine. The overgrowth  of bacteria in 
the intestine cause complex changes and increased intestinal permeability with 
a concomitant decrease  in the expression of tight junction proteins(122).  
 
 Diet rich in fat  causes a rise in  LPS levels two- to three times(123) .  Pro-
inflammatory cytokines  induce inflammatory changes in the liver of  NAFLD 
patients , but research has also proved that  accelerated hepatic steatosis and 
inflammation  occur by the influx of toxic metabolites  into the portal vein in 
animal experiments, when inflammatory signals have been cut off (124) . 
 
 The gut and oral periodontal status have significant positive correlation 
with the onset and development of liver disease(125) . Treating periodontitis 
could cause improved transaminase levels in NAFLD and, in fact, starting on  
probiotics that reduce gut microbiota, improve NAFLD(126 ,127) . Previous 
studies using models of hepatocarcinogenesis have confirmed that a diet rich in 
fat causes increased levels of deoxycholic acid, a  bacterial metabolite from the 
gut, damages DNA and accelerates hepatocarcinogenesis(128). Microbes from 
thegut not only exacerbate NAFLD, but also obesity-linked hepatocarcino-
genesis. 
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Toll-like Receptors (TLRs) 
 Toll-like receptors are sensitve to microbial and endogenous danger 
signals that are expressed   in innate immune cells and in hepatocytes and they 
are linked  to development and  progression of NASH. Gut microbiota might 
produce pathogen- or damage-associated molecular patterns (PAMPs or 
DAMPs), which are TLR ligands that follow the activation of downstream 
signals. Ten TLRs (TLR1-10) have been recognized  in humans and 13 (TLR1-
9, 11–13) were detected  in mammals. TLR2, TLR4, and TLR9 seem to have a 
role in the pathogenesis of NASH.  
 
 Toll-like receptor 2 is a receptor for numerous glycolipids or 
lipoproteins in bacteria adhering to the cell surface of monocytes or mast 
cells.Levels of free cholesterol are increased in hepatic stellate cells (HSC) in 
NAFLD resulting in elevated  TLR4 protein levels and fibrogenic HSCs(129) . 
Kupffer cells are phagocytic cells  that engulf different viral, or bacterial 
components and secrete hepatic pro-inflammatory and pro-fibrogenic 
cytokines. Cholesterol phagocytosed by Kupffer cells can activate these 
cytokines as well as increased expression of TLR4. 
 
Clinical features of NAFLD 
Symptoms and signs of NAFLD 
Majority of NAFLD patients are without any symptoms. Most of them 
are diagnosed,when a liver imaging is done for other unrelated symptoms, i.e., 
when clinical assessment is done for metabolic syndrome. 
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 When symptomatic, they present with, mostly nonspecific symptoms.  
 
 As in other chronic liver diseases, fatigue is the usual complaint. But, 
the severity of fatigue does not vary proportionately with the severity or the 
histological staging of the liver disease(130).  
 
 Few patients complain pain in the right upper quadrant of the abdomen 
(often positional) due to fatty infiltration and its stretching effect on the 
Glisson's capsule.Discomfort may be mistaken for gall stone disease.  
 
 Pruritus is less common with mild edema and on progression, anasarca 
occur only on development of cirrhosis. 
 
 On physical examination, obesity is the predominant clinical feature. 
 
 In other patients, the common clinical features of the metabolic 
syndrome,like hypertension is seen. 
 
 About 30 to 90% of the patients with NAFLD are obese and about half 
of them, present with mild hepatomegaly(131,132), which is usually due to 
steatosis  and may also be due to glycogenesis, in diabetic patients. 
 
 Muscle wasting may occur with progression of the disease, but cannot 
be seen overtly due tocoexistent  obesity in these patients. 
 
 Jaundice may be rarely seen in advanced stages of the disease.  
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 Ascites, splenomegaly, spider angiomas, palmar erythema and caput 
medusae may be present in few patients with NASH-related cirrhosis (133). 
 
AST and ALT in  NAFLD 
 Mild to moderate increase in serum aminotransferase levels is 
commonly found in NAFLD patients( mean range 100 – 200 U/ L). Liver 
enzymes may be normal in a large percentage of patients, and normal levels of 
aminotransferases do not exclude presence of advanced disease. 
 
 Earlier studies have proved that the elevations in alanine 
aminotransferase(ALT) and aspartate aminotransferase (AST) are typically 
mild when present in NAFL and elevated two to three times  the upper limit of 
normal in NASH patients. The AST/ALT  ratiois usually < 1 in patients who 
have either absence or minimal fibrosis, and  this ratio may be  > 1 with the 
progression of fibrosis and development of cirrhosis (134). 
 
 Gamma-glutamyltransferase (GGT) levels are often  increased. 
However,  NAFLD cannot be diagnosed using  GGT alone. Increasing levels of 
serum GGT are  correlated  with increasing severity of fibrosis in NAFLD 
patients. 
 
 Alkaline phosphatase may be slightly increased, and rarelyit may be the 
only abnormal liver function test.Albumin,bilirubin and platelets are usually 
normal and may be increased when cirrhosis develops. 
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 Ferritin levels  are increased in about half the  patients with NASH , and  
transferrin saturation is increased in about 10%. Few NAFLD patients have low 
titres of autoimmune antibodies (anti nuclear and anti smooth muscle 
antibodies) 
 
Ultrasound in NAFLD 
 In asymptomatic patients, ultrasound is a non-invasive and easily 
available tool for diagnosing pathological conditions of the abdomen.It is 
highly accurate in diagnosis, when sonographic criteria specific for  NAFLD, 
are  used in the diagnosis.Bright hepatic echoes, increased hepatorenal 
echogenicity and vascular blurring of portal or hepatic vein are the unique 
sonographic features of NAFLD.The typical findings on ultrasonography have 
been found to be the strongest independent predictor on multivariable analysis. 
 Diffuse steatosis (fatty liver )may be mild , moderate or severe based on 
the following findings. 
 
Mild :Minimal diffuse increase in hepatic echogenecity , normal visualization 
ofdiaphragm  and intra hepatic vessel borders. 
 
Moderate :Moderate diffuse increase in hepatic echogenecity, slightly impaired        
visualization of intrahepatic vessels and diaphragm. 
 
Severe :Marked increase in echogenecity, poor penetration of the posterior 
segment of the right lobe of the liver and poor (or) non visualization of the 
hepatic vessels and diaphragm. 
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 The specificity and sensitivity of ultrasound was found to be about 88% 
to 95% and 60% to 94%.But, the sensitivity diminishes inmilder fatty 
infiltration. When there is ≥ 30%  infiltration of fat, the sensitivity  is 80% but 
it is  55% when hepatic fat content is 10% to 19% (135).  
 
 Moreover, the ultrasonography sensitivity for the detection of steatosis 
progressively decreases as the BMI increases, The  sensitivity is, as low as 39% 
in individuals with BMI of 30 or more. 
 
 Another major drawback of ultrasound is the significant  intra- and 
inter-observer variability. A previous study of 168 ultrasonographicevaluations 
for assessment of hepatic steatosis showed inter- and intra-observers’ 
agreement of 47.0%-63.7% and 54.7%- 67.9%, respectively. 
 
Transient Elastography (Fibroscan) 
 Transient elastography also called fibroscan , is based on measuring 
shear wave velocity.It measures the degree of liver stiffness and thus the degree 
of fibrosis in the liver. 
 
 The probe of the fibroscan device is placed in an intercostal space over 
the right lobe of the liver. A 50 MHz elastic shear wave is transmitted from a 
small transducer at the end of the ultrasound probe into the liver.There is also 
another transducer in the probe, which can detect the speed of the shear wave 
(in meters/ sec) as the wave is transmitted through the liver.The speed of the 
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shear wave is a measure of thestiffness of the liver, which is expressed in 
kilopascals (kpa).The whole process is known as liver ultrasound elastography. 
 
 Fibroscan can measure a liver volume of about 3 sq.cm which is 200 
times > than liver biopsy. 
 
Advantages of fibroscan 
 Non- invasive 
 Point of care testing 
 No pain 
 Sedation is not required 
  Quick test and is completed in 5 to 7 minutes. 
  No side effects 
 
Disadvantages of fibroscan 
      It cannot be used in patients with 
 Ascites 
 Large amount of fat in the chest wall 
 Morbid obesity(136) 
 Fibroscan can detect and quantify steatosis if the Controlled Attenuation 
Parameter (CAP) probe is used(137).It correlates with the decrease in amplitude 
of ultrasound waves as they propogate through the liver fat.It is based on the 
fact that fat affects ultrasound propogation. Hence, the more the steatosis, the 
higher, the CAP result will be. 
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 Computerised tomography,transient elastography,  magnetic resonance 
imaging and magnetic resonance spectroscopy are other newer modalities 
which can directly  measure the quantity of hepatic fat. 
 
Liver biopsy in NAFLD 
 Liver biopsy is currently the gold standard to make a definite and 
accurate diagnosis of the disease.  
 
 It is useful to differentiateNAFLD from other differential 
diagnosis,staging fibrosis, grading activity, for follow up , and assessing the 
response to treatment. But, liver biopsy is unreliable in early cases and has 
numerous disadvantages. They include : 
 
1. Sampling error: Only about 1/50000 of the entire liver isexamined  during 
a liver biopsy.So  sampling error is  a great problem. To avoid this, an 
adequate amount of tissue should be obtained. Collection of 2 or more 
samples from different representative areas will reduce interregional 
variation(138). 
2. Inter and intra-observer  variability–Error in staging fibrosis  is minimized 
by obtaining a specimen  > 2cm in length and 1.5mm diameter with a 
minimal length of 1.5 cm core needle using a 15-16 gauge needle. 
3. Invasive procedure  
4. Bleeding complications(139) 
5. Patient risk 
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6. Pain and inconvenience to the patient 
7. Performance in obese patients 
8. Costly technique 
 
 Therefore, liver biopsy which is an invasive procedure is not practically 
suited for diagnosis of such a common condition. So a simple and noninvasive 
test has to be developed and validated to identify NAFLD.This test should be 
reproducible and reliable, that is both diagnostic and highly accurate to 
differentiate NASH from NAFL and for grading and staging of the disease.It 
should help to noninvasively monitor progression of the disease and response 
to treatment. Numerous researchers have attempted to develop a simple 
biomarker fordiagnosing NASH and Cytokeratin 18 M30is one of them 
 
 
  
Figure 8 : Diagnostic Methods of NASH 
and NAFL 
Figure 9:Non invasive diagnostic methods 
for NASH 
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Cytokeratin 18M30 
Cytokeratins are a family of water insoluble, intracytoplasmic ,fibrous, 
structuralproteins that are the predominant components of intermediate 
filaments of epithelial cells(140,141). 
 The term cytokeratin was first used in the late 1970s by Schmide and 
Frank when the protein was first identified. 
There are two types of cytokeratins:  
   1.  the  type I cytokeratins which are acidic and  
   2.  thetype II cytokeratins which are basic or neutral. 
 
 They usually occur in pairs .Each pair consists of a type Iand a type II 
cytokeratin. 
 
 These proteins are obligate heteropolymers with equimolar 
concentrations of type I and type II proteins(142). 
 
 Cytokeratin 18, a type II protein is expressed on chromosome 12q18:13 
About 25 subtypes have been classified based on molecular weight (from 48 to 
68 kDa) and isoelectric pH (from 6 to 8). 
 
 CK18 couples with CK 8 in the intermediate filaments in the epithelial 
cells of the liver(143).CK 18 amounts to about 5 % of total amount of proteins in 
the hepatic cells and epithelial cells.  
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 Within the cell, cytokeratin filaments form a dense complex network 
radiating from the  nuclear surface to the cell surface. 
 
         They form a cytoplasmic scaffold that gives epithelial cells the ability to 
withstand mechanical as well as thenon mechanicalstress(144). 
 
         The link between the cell surface and the nuclear surface helps in the 
organization of the cytoplasm,providing tensile strength to the cell and also in 
cellular communication mechanisms. They interact with desmosomes and 
hemi-desmosomes to favor cell to cell adhesion and basal cell connective tissue 
interaction(145). 
 
           Apart from the relatively static functions performed by cytokeratin , 
cytokeratin intermediate filaments are highly dynamic structures which 
reorganize during  mitosis and apoptosis. They are important for maintaining 
mitochondrial structures  and for cellular processes like cell-cycle progression 
and cell signaling. 
 
 Reorganization is mediated by post translational phosphorylation, 
glycosylation, transglutamination and proteolysis or by interaction with other 
proteins. 
 
 The intermediate filaments of the cytoskeleton  associate with the 
ankyrin and spectrin complex close to the cell membrane. 
 
Page 50 of 95 
 
 The dynamic equilibrium of  thephosphoglycoprotein CK 18, in the 
soluble and filament pool, determines its cellular functions , and it is proved to 
be regulated by site -specific phosphorylation(146) . 
 
 In NAFLD, severity of disease is due to progressive apoptosis of the 
lipid accumulated cells in the liver. 
 Both the extrinsic and intrinsic pathways of apoptosis start at the 
mitochondria . Permeability of outer mitochondrial membrane promotes 
discharge of proteins from the inter mitochondrial space, into the cytoplasm. 
 
            This causes stimulation of pro-apoptoticcaspases including caspase 3,6 
and 7 (mainly caspase 3) which cleaves many substrates inside the cell causing 
proteolysis of many cellular proteins including cytokeratin 18 in the 
intermediate filaments.During apoptosis, K18 fragments are dramatically 
reorganized and K18 is cleaved by caspases, which are cysteine proteases  at 
multiple sequence sites(147).Cleavage at the C‑terminal domain 396 forms 
CK18–Asp396 neoepitope,known  as M30 antigen . This neo-epitopeis formed 
when caspase cleavage of CK18 occurs at the position after the aspartic acid 
residue 396. Cleavage at this position is executed by caspase 9 in the early 
phase ofapoptosis  and by caspase 3 and caspase 7 in the execution phase . 
 
 Cleavage of K18 is an early event occurring during apoptosis(148). 
Fragmentation of cytokeratin 18 occurs and the fragments are released into the 
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extracellular space during cell death. So soluble cytokeratin 18 is one of the 
factors of hepatocyte apoptosis(149). 
 
 The M30 antibody recognizes this neo-epitope CK18-Asp396.  
Development of the M30 antibody into an ELISA had great clinical utility in 
measuring this specific apoptosis product in the blood. 
 The M30 ELISA measures the amounts of soluble CK18 fragments 
containing the CK18Asp396 neo-epitope.  Caspase-cleaved K18 fragments are 
highly stable in human serum, further making it more convenient andeasy to 
analyze(150). 
 
 The measured levels of CK18M30 in serum, correlates well, with the 
degree of steatosis and the degree of fibrosis in NAFLD patients.Now, it can  
differentiatemoderate and severe fibrosis, especially in progressive cases of 
NAFL and NASH(149). 
 
Serum uric acid levels in NASH 
 Uric acid (2, 6, and 8- Tri hydroxy purine) is a heterocyclic organic 
compound. Its molecular weight is 168 Daltons. It is a weak organic acid with a 
pKa of 5.75. At physiological pH, it significantly exists as urate which has 
higher solubility than uric acid. At a urine pH below 5.75, uric acid is the 
predominant form.  
 
 The amount of uric acid synthesized per day is about 400 mg and from 
dietary source is 300 mg. 
Page 52 of 95 
 
 
 In purine free diet, the total body pool of exchangeable urate is 1200mgs 
in men, and it is about 600mgs in women. It is the end product of purine 
metabolism. 
 Catabolism of purine nucleotides begins by removing ribose linked 
phosphate catalyzed by purine 5’-Nucleotidase. Removal of ribose moiety 
frominosine&guanosine by purine nucleoside phosphorylase produces 
Hypoxanthine and Guanine. Both are converted to xanthine, which is 
catabolised to uric acid by the action of xanthine oxidase. 
 
 Uric acid is degraded in mammalian creatures by enzyme uricase to 
produce allantoin, which is freely excreted in the urine. 
 
 Uric acid is higher in men as well as inpost menopausal women but, 
lower in females because, estrogens are uricosuric. 
 
 Many epidemiological studies have confirmed that uric acid is an 
independent risk factor for metabolic syndrome and cardiovascular disease(151). 
In metabolic syndrome,an inverse correlation exists between insulin resistance 
and renal uric acid clearance which causes elevated serum uric acid 
levels(152).Increased triglycerides synthesis may increase uric acid production 
and excretion. 
 
 A Chinese study confirmed that, a positive association of elevated ALT 
and Met196Arg variant in TNFRSF1B with serum uric acid concentrations 
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among patients with NAFLD(153), supported this proposal called damage 
associated molecular patterns (DAMPS) and proved that release of uric acid 
may be accelerated when tissue injury combined with a genetic susceptibility 
happened in NAFLD. 
 Elevated serum uric acid is independently associated with NAFLD 
regardless of insulin resistance. 
 
Normal reference range: 
 Male: -4.4to7.6 mg/dL,   
 Female: -2.3-6.6 mg/dL 
 
 Increased serum uric acid levels are seen in gout, excess dietary purine 
intake, increased nucleic acid turnover (Leukaemia, Chemotherapy, 
Radiotherapy, trauma) and preeclampsia. 
 
 Hyperuricemia is closely associated with insulin resistance, metabolic 
syndrome and cardiovascular conditions. 
 
 Uric acid has antioxidant properties in the extracellular environment, 
suggesting that it may have a protective role against disease. 
 
 But, multiple studies have shown that when uric acid enters cells via 
specific transporters it has a pro-inflammatory role. Inside the cell, uric acid 
can actas a pro-oxidant, causing the release of inflammatory mediators and 
growth factors. 
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 Moreover, uric acid has been proved to contribute to lipoprotein 
oxidation andinflammation,which are important mechanisms in the 
development and progression of NAFLD. Preliminary evidence suggests that 
hypouricemic therapy can reduce the degree of hepatic steatosis in 
experimental studies. 
  
Aims & objectives 
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AIM OF THE STUDY 
 
1. To evaluate the  levels of serum cytokeratin18M30 in the various stages of 
non alcoholic fatty liver disease – simple fatty liver (steatosis) and non 
alcoholicsteatohepatitis(NASH)  diagnosed by ultrasound and transient 
elastography (fibroscan) and compare it with apparently healthy controls . 
 
2. To correlate  lipid profile (Total cholesterol,serum triglycerides, low density 
lipoprotein and high density lipoprotein) and serum uric acid with 
cytokeratin18M30  in various stages ofNAFLD. 
 
 
 
 
 
 
  
Materials & methods 
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MATERIALS & METHODS 
 
 This is a cross sectional case control study and was conducted after 
getting ethical committee approval. The study comprised of a total number of 
85 subjects including 35 patients of simple fatty liver  and 25 patients of NASH 
diagnosed by ultrasonography in the Medical gastroenterology departments and 
Medical  departments (outpatient and inpatients) and 25 normal controls in 
Rajiv Gandhi Government  General Hospital, Chennai. 
 
Inclusion criteria : 
 Cases of NAFLD including non alcoholic fatty liver (NAFL)and non 
alcoholicsteatohepatitis (NASH) diagnosed by ultrasonography and transient 
elastography (fibroscan). 
 
Exclusion criteria: 
 Patients with history of alcohol consumption (> 30 g /day for males and 
20 g / day for females) 
 Viral hepatitis 
 Autoimmune liver diseases 
 Hepatocellular carcinoma patients. 
 Congenital liver diseases 
 
 Cases were selected based findings of fatty liver and fibrosis 
(steatohepatitis) in ultrasonography and transient elastography. 
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They were divided into two groups- 
1. Non alcoholicfatty liver (NAFL)  
2. Non alcoholic fatty liver (NASH). 
 
 Non alcoholic simple fatty liver was diagnosed based on the findings of 
fatty liver (steatosis) – grade 1, 2 or 3 by ultrasonography with normal findings 
on fibroscan (< 7 kpa). 
 
 NASH was diagnosed based on,ultrasonographicfindings of fatty liver 
and fibroscan values of > 7 kpa and elevated ALT  and AST levels (twice or 
thrice normal) or AST/ALT ratio > 1. 
 
In our Hepatology department fibroscan values are interpreted as follows 
<7 kpa  -  Normal 
         7 to 9 kpa – Early fibrosis 
9  to 13 kpa – Advanced fibrosis 
>13 kpa - cirrhosis 
 
 A control group with normal ultrasonographic findings with normal 
fibroscan findings was also included in the study. 
 
Blood sample collection: 
 Blood was collected after 8-12 hrs of overnight fasting. 
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 About 5mL of venous blood  was collected from  antecubital vein after 
aseptic precautions  and transferred in to 2 tubes and the investigations 
performed as per the following table. 
 
 
Tubes Anticoagulant Amount of blood Investigations 
Tube1 --- 3Ml 
Serumcytokeratin18M30, 
Fasting Plasma Lipid 
profile,AST,ALT,ALP,Uric 
Acid. 
Tube2 EDTA 3Ml Fasting Plasma Glucose 
 
 The blood samples were  analysedwith in 4 hrs of sample  collection and 
were analysed by the  following methodologies. 
 
Estimation of serum cytokeratin 18 M30 
Method:Quantitative sandwich enzyme immunoassay. 
Kit from Cusabio 
 
Principle. 
 A monoclonal antibody specific for CK 18- M30  is already precoated  
on to a microplate. 
 Samples and standards are pipetted into the  microplate wells and the 
CK-18M30 present is bound by the immobilized antibody. 
 After removal of any unbound substances ,a biotin- conjugated antibody 
specific for CK 18-M30 is pipette into the wells. 
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 The microplate wells are then subjected to washing ,avidin conjugated 
Horse Radish Peroxidase (HRP) is pipetted into the wells. 
 Any unbound avidin-enzyme reagent is removed by further washing. 
 Then a substrate solution is pipettedinto the wells and a color develops 
which is proportional to the amount of CK 18-M30 present in the 
samples. 
 The colour development is stopped & intensity of colour is measured at 
540 nm and 450 nm.The difference between the two readings is taken 
for correction of optical imperfection in the plate. 
 Reagent composition: 
1. CK 18-M30  microplate -96  microwells coated with CK 18-M30  
monoclonal antibody. 
2. CK 18-M30 standard (freeze dried) – 2Nos 
3. Biotin- antibody -120μL 
4. HRP - avidin-  120μL 
5. Wash buffer concentrate –  20 mL 
6. Sample diluent -50 mL 
7. Wash buffer concentrate – 20 Ml 
8. TMB substrate –10 mL 
9. Stop solution -  10 mL 
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Working reagent preparation: 
 Biotin - antibody :-  must be diluted 100 times . 10 μL of Biotin 
antibody added to 990 μL of Biotin antibody diluent. 
 HRP - antibody :-  100 times dilution is needed  . 10 μL of HRP  
antibody added to  990 μL of HRP antibody diluent. 
 Wash Buffer Concentrate is diluted (x25) by diluting 20 mL into 480 
mL of deionised water  500 mL of wash buffer is prepared. 
 
PREPARATION OF STANDARD 
 The freeze dried standard is mixed with 1.0 mL of sample diluent. 
Allow it to sit for 15 minutes with gentle agitation beforemaking  
serialdilutions. 
 250 μL of Sample diluent is pipetted into 7 tubes (S0 to S6). 
 Using the stock solution a two- fold dilution series is prepared .Each 
tube is mixed thoroughly before the next transfer. 
 The undiluted standard acts as the high standard (1000 m IU /mL). 
 Sample diluent  is the zero standard (0 m IU / mL).  
 
 
 
  
Tube S7 S6 S5 S4 S3 S2 S1 S0 
mIU/mL 1000 500 250 125 62.5 31.2 15.6 0 
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PROCEDURE 
 All reagents and working standards are prepared. 
 100 μL of standard and sample is added in each well. 
 The plate is covered with adhesive strip and incubated at 37°C for 2 
hours. 
 Without washing the liquid of each well is removed. 
 100μL of biotin antibody is added to each well. 
 Plate is covered and incubated at 37°C for 1 hour. 
 After aspirating each well, the wells are washed, repeating the process 
twice for a total of three washes. 
 100μL of HRP – avidin is added to each well . 
 Plate is covered and incubated at 37°C for 1 hour. 
 The aspiration / wash process is repeated  five times. 
 90 μL of TMB subsrate is added to each well. 
 Plate is covered and incubated for 15 – 30 minutes at 37° C. 
 50 μL of Stop solution is added to each well and gently tapped for 
thorough mixing. 
 The optical density of each well is measured within 5 minutes, using a 
micro-plate reader, set to 450 nm. 
 The reader is set again to 540 nm and a second measurement is taken. 
 The  readings at 540 nm is subtracted from the readings at 470 nm. (this 
allows correction for optical imperfections in the plate). 
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Calculation: 
 A standard  curve  was constructed  by  plotting  the  concentration  on 
the x-axis  and  the mean absorbance of each  standard  on the Y-axis  and  a 
best  fit  curve  was  drawn  through  points on the  graph. 
 
 The  following  table  shows  the  absorbance (OD) of each  standard 
and the  concentration  of CK 18M30 in the sample was  obtained  based  on 
this  absorbance. 
 
Standard(mIU/mL） O.D 
1000 2.546 
500 2.003 
250 1.314 
125 0.674 
62.5 0.382 
31.2 0.281 
15.6 0.206 
0 0.121 
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STANDARD CURVE OF CK 18M30 
 
 
Reference range: 
Healthy : < 150 U/L 
Slightly elevated : 150 – 200 U/L (indication for mild fibrosis as in NAFL) 
Elevated : > 200 U/L (substantial fibrosis as in NASH) 
 
ANTHROPOMETRIC MEASUREMENTS 
      Height is measured in meters,weight is measured in kilograms and Body 
mass index is calculated as: 
                           Weight (kg) 
                     ________________  
                            Height (m2) 
It has been used as an estimate of overall adiposity. 
Normal weight - 18.5 to 24.5 
Overweight - 25 to 29.9 
Obesity > 30 
S = 5.81491627
r = 0.99991959
Optical Density
C
on
ce
nt
ra
tio
n
0.0 0.5 0.9 1.4 1.9 2.3 2.8
0.00
183
.33
366
.67
550
.00
733
.33
916
.67
110
0.00
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ANALYTES 
Automated chemistry analyzer ERBA 640 was first calibrated using the XL 
MULTICAL calibrator traceable to Isotope dilution mass spectrometry(IDMS). 
Plasma glucose,total cholesterol, triglycerides,HDL uric acid,AST and ALT 
were analysed using ERBA 640 automated analyser.. Results were calculated 
automatically by the instrument 
ESTIMATION OF PLASMA GLUCOSE 
 Method:  Glucose Oxidase -  Peroxidase Method  (GOD – POD) End 
point assay 
Glucose in the sample is oxidized to gluconic acid and hydrogen peroxide in 
the presence of Glucose oxidase. The enzyme peroxidasecatalyses the oxidative 
coupling of 4-aminoantipyrine with phenol to yield a colouredquinonemine 
complex.The intensity of the colourisdirectly  proportional to the concentration 
of glucose in sample. 
 
       Glucose oxidase 
β-D-Glucose + H2O + O2                                                  Gluconic acid + H2O2 
         Peroxidase 
H2O2 + phenol + 4AAP     Quinoneimine + 2H2O 
4AAP – 4 amino antipyrine. 
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REAGENT COMPOSITION 
ACTIVE INGREDIENT CONCENTRATION 
PHOSPHATE BUFFER 250  mmol/L 
GLUCOSE OXIDASE 25 U/Ml 
PEROXIDASE >2 U/mL 
PHENOL 5 mmol/L 
4  - AMINOANTIPYRINE 0.5  mmol/L 
 
 
Procedure: 
 Automated chemistry analyzer ERBA 640 was first calibrated using the 
XL MULTICAL calibrator traceable to Isotope dilution mass 
spectrometry(IDMS) . Results were calculated automatically by the instrument 
Reference interval: Fasting plasma Glucose = 70-100 mg/dL. 
 
ESTIMATION OF TOTAL CHOLESTEROL  : 
 Method : Cholesterol esterase – cholesterol oxidase 
 End point assay 
 
PRINCIPLE 
     Cholesterol esterase                   
Cholesterol ester+H2o                                              Cholesterol +Fatty acids. 
                               Cholesterol Oxidase   
Cholesterol+O2                                                Cholestenone+H2O2 
                                           Peroxidase 
2H2O2  +4AAP+            Phenolquinoneimine dye+4 H2O. 
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REAGENT COMPOSITION 
REAGENT 1 
 
 
Reference interval: 
Desirable   :   <200mg/dL 
Borderline high :  200-230 mg/dL 
High   : >239 mg/dL 
 
TRIGLYCERIDE: 
 Method   : Enzymatic colorimetric method 
 End point assay 
 
PRINCIPLE 
 The series of reactions involved in the assay system is as follows:  
                      Lipoprotein Lipase 
TGL+H2O                    glycerol+ free fatty acids. 
   Glycerol Kinase 
Glycerol+ ATP                                       glycerol-3-phosphate +ADP 
ACTIVE INGREDIENT CONCENTRATION 
GOOD’ S  BUFFER 50 mmol/L 
PHENOL 5 mmol/L 
4 AMINO ANTIPYRINE 0.3 mmol/L 
CHOLESTEROL ESTERASE ≥   200 U/L 
CHOLESTEROL OXIDASE >50 U/L 
PEROXIDASE >3 kU/L 
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    glycerol-3-phosphate oxidase 
Glycerol-3-phosphate+O2                                                                   DAP+ H2O2                                                                   
 
H2O2  +4AAP+ 4 chlorophenol    Red Quinone +2H2O 
*DAP – Dihydroxy acetone phosphate 
 
REAGENT COMPOSITION 
Active Ingredient Concentration 
Good’s buffer (pH 7.2) 50 mmol/L 
4-Chlorophenol 4 mmol/L 
Mg 2+ 15 mmol/L 
ATP 2 mmol/L 
Glycerolkinase ≥ 0.4 KU/L 
Peroxidase ≥ 2.0 KU/L 
Lipoproteinlipase ≥ 2.0 KU/L 
Glycerol-3-phosphate-Oxidase ≥ 0.5 KU/L 
4-Aminoantipyrine 0.5 mmol/L 
 
Reference values: 
Males:60-165mg/dL 
Females:40-140mg/dL. 
 
Estimation of HDL-Cholesterol: 
Principle: 
 The assay is based on a modified polyvinyl sulfonic acid (PVS) and 
polyethylene-glycol-methyl ether (PEGME) coupled classic precipitation 
method with the improvements in using optimized quantities of PVS/PEGME 
Peroxidase 
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and selected detergents.LDL, VLDL and chylomicron (CM) react with PVS 
and PEGME and the reaction results in inaccessibility of LDL, VLDL and CM 
by cholesterol oxidase (CHOD) and cholesterol esterase (CHER). 
The enzymes selectively react with HDL to produce H2O2 which is detected 
through a Trinder reaction.            
            PVS 
         PEGME 
HDL+LDL+VLDL+CMHDL +           (LDL + VLDL + CM) + PVS/PEGME 
  CHOD, CHER 
HDL                               Fatty Acid + H2O2 
     Peroxidase 
2H2O2 +4-AA+TODB             Quinone + 5 H2O 
REAGENT COMPOSITION 
R1 
Active Ingredient Concentration 
MES buffer (pH 6.5) 6.5 mmol/L 
TODB N, N-Bis(4-sulfobutyl-3-
methylaniline) 3 mmol/L 
Polyvinyl sulfonic acid 50 mg/L 
Polyethylene-glycol-methyl ester 30 mg/L 
MgCl2- 2 mmol/L 
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R2 
Active Ingredient Concentration 
MES buffer (pH 6.5) 50 mmol/L 
Cholesterol esterase 5 kU/L 
Cholesterol oxidase 20 kU/L 
4-aminoantipyrine 0.9 g/L 
Detergent 0.5 % 
 
 
Reference interval: 
 Low: <40 mg/dL 
          High > 50 mg/dL 
 
URIC ACID ESTIMATION: 
PRINCIPLE 
End point assay 
This reagent is based onTrinder reaction. The following are the reactions 
involved . 
    Uricase 
Uric Acid + O2 + H2O                    Allantoin + CO2 + H2O2 
 
     Peroxidase 
TOOS + 4AAP + 2H2O2    Quinoneimine dye + 4H2O 
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REAGENT COMPOSITION 
R1 
Active Ingredient Concentration 
Pipes Buffer (pH 7.0) 50 mmol/L 
4-Aminoantipyrine 0.375 mmol/L 
Uricase ≥200 U/L 
 
R2 
Active Ingredient Concentration 
Pipes Buffer (pH 7.0) 50 mmol/L 
TOOS 1.92 mmol/L 
Peroxidase ≥5000 U/L 
 
Reference interval: 
 Male:    4.4 to 7.6 mg/dL 
 Female: 2.3 to 6.6 mg/dL 
ALT 
PRINCIPLE 
This ALT/GPT reagent is based on the recommendations of the IFCC without 
pyridoxal phosphate.  
ALT/GPT 
L-Alanine + 2-oxoglutarate                        Pyruvate + L-Glutamate 
 LDH 
Pyruvate + NADH                   L-Lactate + NAD 
 LDH 
Sample pyruvate + NADH                    L-Lactate + NAD 
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REAGENT COMPOSITION 
R1 
Active Ingredient Concentration 
Tris buffer (pH 7.5)  137.5 mmol/L 
L-Alanine  709 mmol/L 
LDH (microbial)  ≥ 2000 U/L 
 
R2 
Active Ingredient Concentration 
CAPSO  20 mmol/L 
2-oxoglutarate  85 mmol/L 
NADH  1.05 mmol/L 
 
Reference interval: 
Male: <45U/L 
Female: <34U/L 
ESTIMATION OF AST: 
PRINCIPLE 
This reagent is based on IFCC recommendations, without pyridoxal phosphate. 
The series of reactions involved in the assay system is as follows: 
AST/GOT 
L-Aspartate + 2-oxoglutarate                         Oxaloacetate + L-Glutamate 
MDH 
Oxaloacetate + NADH                   Malate + NAD 
  LDH 
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Sample pyruvate + NADH                   L-lactate + NAD 
REAGENT COMPOSITION 
R1 
Active Ingredient Concentration 
Tris buffer (pH 7.8)  110 mmol/L 
L-aspartic acid  340 mmol/L 
LDH  ≥ 4000 U/L 
 
R2 
Active Ingredient Concentration 
CAPSO  20 mmol/L 
2-oxoglutarate  85 mmol/L 
NADH  1.05 mmol/L 
Reference interval: 
Male: <35 U/L 
Female :<31U/L 
 
ULTRASOUND ABDOMEN 
 Ultrasound abdomen has been performed for all patients to find out the 
echogenic pattern characteristic of visceral fatty liver.The patients are graded 
as having grade 1, grade II or grade III fatty liver with (or) without 
hepatomegaly. 
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TRANSIENT ELASTOGRAPHY (FIBROSCAN) 
 Fibroscan was performed for those patients diagnosed as fatty liver on 
ultrasound and those patients with elevated AST and ALT levels.This was 
performed with a special probe which was placed in the right upper quadrant  
of the abdomen.This measured the fibrosis of the liver (stiffness of the liver) in 
kilopascals. 
 
A value of < 7 kpa is normal. 
 7-13kpa   fibrosis. 
 > 13kpa cirrhosis. 
 
  
Statistical analysis 
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STATISTICAL ANALYSIS 
 
 Data was analyzed using SPSS software version 16.0 and P value less than 
0.05  was considered as statistically significant. 
 BMI, total cholesterol,triglycerides ,HDL, plasma glucose and uric acid 
were compared between study groups by Student’s t-test. 
 The association of BMI,Total cholesterol, Triglycerides ,HDL, and Uric 
acid, with cytokeratin 18M30 were studied  by Pearsons correlation method. 
 One way ANOVA was done to compare more than two variables in the 
same group & between two group . It was carried out to compare 
Cytokeratin 18 M30  between NAFL& NASH  patients. 
 Receiver operating characteristics curve analysis was done to assess the 
utility of cytokeratin 18M30 in the diagnosis of NASH. 
 Serum Cytokeratin 18M30 levels between the groups were analyzed by 
regression analysis and scatter diagram plotted. 
  
Results 
  
Sno Age Gender Height cm Weight kg
BMI  
kg/m^2
CK18M30 
U/L
Fastng PG 
mg/dL
Total 
cholester
ol mg/dL
TGL 
mg/dL
HDL 
mg/dL
Uric Acid 
mg/dL
AST U/L ALT U/L
Utrasono 
gram
Fibro 
Scan
Diabetes 
mellitus
1 56 M 156 72 29.59 184.56 87 156 145.3 38 6.1 85 48 FL 6 Y
2 33 F 149 52 23.42 198.99 94 208 179 39.4 6 43 31 FL 6 N
3 56 F 143 61 29.83 187.67 114 206 122.2 33 4.8 48 38 FL 6 N
4 57 F 145 56 26.63 189.14 87 189 198.4 27.3 6.3 17 30 FL 6 N
5 30 F 154 50 21.08 219.56 108 212 117.3 43 3.91 81 20 FL 7 Y
6 44 M 162 61 23.24 159.34 99 186 145 47 5.7 49 53 FL 2 N
7 56 F 142 62 29.09 165.89 110 193 140.4 35.7 3.9 49 67 FL 3 Y
8 64 M 158 65 26.04 178.34 90 188 210 26.8 10.56 45 47 FL 6 N
9 61 F 162 70 26.67 185.14 111 201 221 31.6 3.45 33 44 FL 6 Y
10 42 F 140 54 27.55 202.45 101 229 194 27.8 8.15 29 28 FL 7 N
11 54 F 144 72 34.72 201.87 116 206 126 32 5.9 48 84 FL 7 Y
12 53 F 148 65 29.67 189.18 108 151 162.4 49.6 4.8 45 22 FL 6 N
13 48 F 154 56 27.83 187.34 98 156 145.5 34.5 4.6 19 29 FL 6 N
14 31 F 135 44 24.14 167.43 99 126 71.8 47.8 2.34 23 51 FL 3 N
15 35 F 143 53 25.92 197.56 87 146 133.4 42.4 4.2 19 89 FL 6 N
16 56 M 159 68 26.9 188.45 89 214 168 42 7.25 32 24 FL 6 Y
17 36 F 138 36 30.46 168.11 89 153 186 39 5.3 36 33 FL 4 N
18 58 M 161 70 27.01 198.56 103 156 118 52.5 6.5 56 29 FL 6 N
19 26 M 151 68 29.8 176.89 99 231 278.9 47.3 6.3 31 24 FL 5 N
20 47 M 151 62 27.19 185.56 113 167 143 38 7.2 34 27 FL 6 Y
21 48 M 159 68 26.9 162.11 67 117 111.4 51 6.9 28 35 FL 3 N
22 29 M 143 52 25.43 150.23 95 127 125 32 4.78 45 47 FL 2 N
23 60 F 153 68 29.05 168.95 89 162 167 43 5.1 56 11 FL 4 N
24 43 M 153 65 27.77 156.45 98 158 132.5 44.5 4.34 67 32 FL 2 N
25 68 F 153 60 25.63 178.87 87 242 125.9 27.8 1.84 45 30 FL 6 N
26 63 M 142 65 32.24 167.54 122 231 278.9 47.3 5.4 49 29 FL 3 N
27 45 F 154 62 26.14 155.87 97 143 110.5 41 2.3 30 46 FL 2 N
28 45 F 155 65 27.06 176.98 97 153 147 38.1 3.4 29 10 FL 5 N
29 69 F 151 72 23.24 153.14 109 152 183.7 41.8 5.3 29 19 FL 2 N
30 60 M 163 66 24.84 151.64 97 156 143.8 42 5.34 34 58 FL 2 N
31 61 M 165 70 25.71 175.61 117 168 155 41.5 5.3 37 18 FL 5 N
32 52 F 156 59 24.24 204.45 124 168 154 38 6 15 38 FL 7 N
33 40 M 159 61 24.13 197.67 118 210 165 29 7.1 34 46 FL 6 N
34 55 F 142 54 26.78 194.45 111 206 147.8 28 4.9 29 30 FL 6 N
35 54 M 160 74 28.01 168.45 107 235 198.5 41.3 4.6 22 51 FL 4 N
Master Chart of NAFL Patients
FL  - Fatty liver
Sno Age Gender Height cm Weight kg
BMI  
kg/m^2
CK18M30 
U/L
Fastng PG 
mg/dL
Total 
cholester
ol mg/dL
TGL 
mg/dL
HDL 
mg/dL
Uric Acid 
mg/dL
AST U/L ALT U/L AST/ALT
Utrasono 
gram
Fibro Scan
Diabetes 
mellitus
1 43 F 148 59 26.94 263.87 96 244 222.5 25.4 6.8 15 33 0.93 FL 8 N
2 64 M 146 60 28.15 498.45 131 231 220.5 26.5 6.4 48 94 0.93 FL 11 Y
3 68 F 145 67 31.87 705.89 142 248 242.5 23.2 3.4 29 30 1.17 FL 20 N
4 49 M 146 61 28.62 504.67 100 248 239.8 26.8 6.1 34 43 0.97 FL 11 Y
5 54 M 157 68 27.59 554.38 107 196 187.5 31.5 6.8 22 87 1.19 FL 13 N
6 57 M 161 75 28.93 664.98 80 356 388.6 19.6 5.6 39 35 1.13 FL 16 N
7 56 F 150 61 27.11 668.56 129 178 181.3 29.6 4.9 21 28 1.10 FL 16 Y
8 34 M 158 70 28.04 487.65 116 196 201.4 31.5 14.3 24 34 0.85 FL 11 Y
9 46 M 162 68 25.91 330.78 94 178 165.3 37.8 6.1 35 54 0.89 FL 9 Y
10 49 F 140 68 34.69 765.64 134 276 323 24.4 9.8 30 34 1.19 FL 24 Y
11 56 F 148 71 32.41 239.78 123 179 163.6 42.6 4.9 29 39 0.83 FL 8 Y
12 44 M 142 70 34.72 226.67 129 246 198.6 23.1 8.4 23 49 0.88 FL 8 Y
13 56 F 159 69 27.29 553.87 99 208 256 25.8 3.4 28 28 0.62 FL 12 N
14 43 M 164 79 29.37 605.89 96 303 288.5 22.7 14.3 30 30 1.33 FL 15 N
15 53 M 169 74 25.91 443.35 99 187 198.5 26.7 5.8 26 31 0.82 FL 10 N
16 58 M 150 64 28.44 456.85 110 258 232.5 23.2 7.3 42 49 0.92 FL 10 N
17 42 M 164 82 30.49 677.98 124 298 288.8 20.8 5.8 56 29 1.09 FL 17 Y
18 40 F 153 61 26.05 276.67 87 167 144.4 47.3 2.5 56 64 0.89 FL 8 N
19 56 F 149 64 28.83 705.45 91 167 156.5 45.8 5.2 48 17 1.12 FL 20 N
20 60 M 153 65 27.77 453.87 115 267 256 27.1 5.7 76 20 0.92 FL 10 Y
21 67 M 157 75 30.43 774.87 133 278 365.5 21.2 6.1 33 58 1.19 FL 25 Y
22 57 F 158 65 26.04 233.14 93 178 156 38.1 6.1 29 23 0.89 FL 8 Y
23 62 F 142 65 32.24 554.89 99 248 242.5 23.2 5.2 47 32 1.08 FL 13 N
24 55 F 151 68 29.82 450.67 120 229 198.5 21.4 4.9 34 50 0.93 FL 10 Y
25 50 M 159 68 26.9 331.78 115 211 208 27.8 5.8 76 78 0.46 FL 9 Y
Master Chart of NASH Patients
FL - Fatty  Liver
Sno Age Gender Height cm Weight kg
BMI  
kg/m^2
CK18M30 
U/L
Fastng PG 
mg/dL
Total 
cholesterol 
mg/dL
TGL 
mg/dL
HDL 
mg/dL
Uric Acid 
mg/dL
AST U/L ALT U/L
Utrasono 
gram
1 23 F 143 43 21.03 64.45 89 164 173.3 38.8 4.9 23 11 N
2 34 M 149 50 22.52 78.56 91 156 167 43.7 3 33 38 N
3 36 M 158 59 23.63 84.45 108 183 164 51.8 4.1 29 25 N
4 40 M 154 56 23.61 78.76 104 190 75.7 65.9 5.1 39 29 N
5 28 F 146 51 23.93 78.87 99 170 75 50.6 4.9 21 31 N
6 44 M 154 55 23.19 83.54 102 164 167.3 52.8 2.67 30 26 N
7 20 M 150 56 24.89 83.56 94 176 178.5 34.4 6.3 29 29 N
8 35 F 151 51 22.37 77.86 101 178 165.4 51.8 1.9 19 10 N
9 33 F 155 54 22.48 67.57 76 176 156.4 39.8 5.2 31 29 N
10 38 M 161 64 24.69 88.67 101 163 134.8 45.8 2.3 34 19 N
11 38 M 149 48 21.62 63.86 75 184 86 42.3 3.8 32 28 N
12 52 F 148 44 20.09 56.56 71 141 114.1 34.5 4.9 31 13 N
13 29 M 159 60 23.73 78.87 78 174 162.8 42.5 4.76 33 20 N
14 56 M 154 58 24.46 82.58 98 146 154.3 42.7 4.5 10 43 N
15 34 F 156 55 22.6 75.67 89 168 144.4 48.7 1.78 28 32 N
16 34 F 149 52 23.42 77.65 94 143 177.7 36.7 2.96 26 19 N
17 30 F 151 55 24.12 83.98 107 193 140.4 52.4 4.5 19 44 N
18 37 M 152 50 21.64 64.56 68 174 163.5 40.1 4.7 35 38 N
19 33 M 158 58 23.23 84.01 95 145 110.8 56.5 3.4 34 20 N
20 37 F 153 54 23.07 76.56 65 167 175.5 38.6 5.4 22 34 N
21 31 F 147 58 26.84 94.76 60 189 151.5 42.6 3.56 13 23 N
22 38 M 150 46 20.44 56.87 98 148 148.3 52.5 2.46 39 29 N
23 56 M 155 55 22.89 80.03 84 139 145.6 38.9 4.1 29 36 N
24 33 F 142 48 23.8 76.45 97 178 165.6 54.3 1.78 20 19 N
25 37 M 148 50 22.83 68.86 89 154 163 38.7 4.9 28 38 N
N - Normal
Master Chart of Controls Group
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RESULTS OF THE STUDY 
 
Table:1    Comparison of age between NAFL and NASH 
Age NAFL NASH 
20 – 30 2 0 
30-40 5 2 
40 –50 9 8 
50 – 60 11 10 
60 – 70 8 5 
 
There were 9 ,11 and 8 patients of NAFL in the fourth ,fifth and sixth decades. 
There were 2,8 and 10 patients of NASH in the fourth,fifth and sixth decades. 
 
Figure 10:Bar diagram showing comparison of age between  
NAFL and NASH 
 
 Occurrence of NASH and NAFL is much higher in 40-50, 50-60 and 
60-70 age group compared to 20 -30 and 30-40 age group. 
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Table 2 :BMI in NAFL and NASH compared to healthy controls. 
 No Mean Standard Deviation 
Standard      
Error of Mean p value 
NASH 25 28.98 2.56 .512 
 
0.004 NAFL 35 25.81 1.67 .282 
CONTROLS 25 24.22 1.08 .217 
 
p value   0.004 
 
 TABLE 2: shows the comparison of BMI between NAFL ,NASH and 
healthy controls. The mean BMI in the control group was 24.22 (+/-1.08)  and 
in the NAFL group was 25.81 (+/- 1.67) and in the NASH group was 28.98 (+/-
2.56). A significant p valueof 0.004was obtained. 
 
Table 3 :Comparison of cytokeratin 18m30 in NAFL and NASH with 
healthy controls - anova 
 No. MEAN STANDARD DEVIATION 
STANDARD 
ERROR OF 
MEAN 
p 
value 
CONTROLS 25 76.30 9.56 1.91 
 
< 
0.01 
NAFL 35 179.84 17.45 2.94 
NASH 25 497.22 173.67 34.73 
 
 Usinganovatest,TABLE – 3 shows  Cytokeratin 18M30  in various 
stages of NAFLD including NAFL and NASH compared to healthy controls. 
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 The mean Cytokeratin 18 M30 in NAFL was found to be 179.84 (+/-
17.45) and in NASH was 497.22 (+/- 173.67) and in the control group was 
76.30 (+/- 9.56).There was statistically significant difference in CK 18M30 
levels between the three groups with the highest being in NASH compared to 
NAFL and controls.A highly significant p value of <0.01 was obtained . 
 
Figure11: Bar diagram of cytokeratin 18m30 levels in NASH, NAFL 
compared to controls 
 
1.Controls   2.NAFL  3. NASH 
Cytokeratin 18M30 levels are greatly elevated in NASH compared to NAFL 
and controls. 
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Figure 12:Regression analysis - scatter plot of cytokeratin 18m3o in 
NASH, NAFL and controls 
 
 
 
 Scatter plot shows linear plot with positive gradient of cytokeratin 
18M30.It also shows highly elevated levels of cytokeratin 18M30 in NASH 
compared to NAFL and controls. 
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Figure13: ROC (receiver operating characteristics) curve for cytokeratin 
18m30 in NASH 
 
 
 ROC curve plotted between cytokeratin 18M30 levels and fibroscan in 
NASH shows specificity of 92.9 % (highly specific), sensitivity of 
81.8%(moderately specific), at a cut off point of 553.87U/L. Area under the 
curve (AUROC) is  0.922, with a highly significant p value of < 0.01(95% CI 
of 0.742 to 0.990). 
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TABLE 4 :Lipid profile in NAFL, NASH and healthy controls 
  N MEAN STANDARD DEVIATION 
STANDARD           
ERROR OF    
MEAN 
p 
value 
TOTAL 
CHOLESTEROL 
CONTROLS 25 158.92 15.99 3.19 
0.019 NAFL 35 217.54 46.34 7.83 
NASH 25 225.88 27.40 5.48 
TRIGLYCERIDES 
CONTROLS 25 146.43 30.78 6.15 
0.007 NAFL 35 175.98 34.42 5.81 
NASH 25 178.23 18.57 3.71 
HDL 
CONTROLS 25 45.49 7.86 1.58 
0.002 NAFL 35 38.67 5.81 0.98 
NASH 25 28.40 7.64 1.52 
 
 TABLE 4: shows the data Total cholesterol,Triglycerides and HDL in 
NAFL , NASH compared to healthy controls. 
 A significant p value was obtained for Total cholesterol, Triglycerides 
and HDL. 
1. The meantotal cholesterol in NAFL was (217.54+/-46.34) and 
inNASHwas  (225.88 +/- 27.40) with a  p value of 0.019. 
2. The mean triglycerides in NAFL was (175.98 +/-  34.42 ) and in NASH 
was (178.23+/- 18.57 ) with a  p value of 0.007. 
3. The mean HDL in NAFL was (38.67 +/- 5.81 ) and in NASH (28.40 +/- 
7.64 ) with a  p value of 0.002. 
 This table shows statistically significant difference between NASH and 
NAFL group, and NASH and control group regarding total 
cholesterol,triglycerides  HDL. 
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Figure 14 :Shows normal and abnormal frequency of lipid profile in 
NAFL 
 
Total cholesterol was elevated in 60% ,triglycerideswas elevated in 66% and 
HDL was decreased in 63% of NAFL cases. 
 
Figure 15 : Shows  normal and abnormal frequency of lipid profile in 
NASH 
 
Figure 15 shows total cholesterol was increased in 84%, triglycerides was 
increased  in 80% and HDL was decreased in 84 % of NASH cases. 
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Table 5 : Comparison of fasting plasma glucose levels between NAFL, 
NASH and controls 
 No Mean Standard Deviation 
Standard 
error of 
Mean 
p value 
 
CONTROLS 25 84.20 11.46 2.29 
 
0.003 NAFL 35 104.86 10.57 1.78 
NASH 25 111.48 15.95 3.19 
 
   The mean fasting blood plasma glucose was 84.20 (+/- 11.46) in the control 
group,104.86 (+/- 10.57) in the NAFL group and 111.48 (+/- 17.122) in the 
NASH group with a significant p value of 0.003.There was stastistically 
significant difference in FBS levels between NASH and NAFL  group, and 
between NASH and control groups. 
Figure 15: Shows frequency of normal and abnormal fasting plasma 
glucose in NASH and NAFL groups 
 
Poor glycemic control was seen in 60% NAFL and 60% NASH cases. 
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Table 6: Comparison of uric acid between NAFL,NASH and controls 
 No Mean Standard     Deviation 
Standard error 
of Mean p value 
CONTROLS 25 3.91 1.26 0.25 
 
< 0.001 NAFL 35 6.33 1.19 0.20 
NASH 25 6.81 2.51 0.50 
 
 The mean uric acid in the NASH group was 6.81(+/-1.19) and in the 
NAFL group was 6.33(+/- 2.51) and in the control group was 3.91(+/-1.26) 
with a highly significant p value of <0.001.There was statistically significant 
difference in uric acid levels between NASH and NAFL groups, and NASH 
and control groups. 
 
Table   7 :  Comparison of liver enzymes AST and ALT between NAFL 
NASH and controls 
  No Mean Standard Deviation 
Standar
d Error 
of Mean 
 
p  value 
AST 
CONTROLS 25 25.56 8.46 1.69 
 
0.004 NAFL 35 34.60 11.36 1.92 
NASH 25 102.96 31. 6.20 
ALT 
CONTROLS 25 32.52 8.58 1.71 
 
0.001 NAFL 35 46.86 14.23 2.40 
NASH 25 109.60 27.19 5.43 
 
 TABLE 7:   AST, ALT and ALP were compared between the study 
groups.The mean AST in NAFL was (34.60+/-11.36) and in NASH (102.96+/-
31)with a significant p value of 0.004 . The mean ALT in NAFL was (46.86+/-
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14.23 ) and in NASH (109.60+/- 27.19)  with a significant p value of 
0.001.There was stastistically significant difference between NASH and control 
group and between NAFL and control groups in uric acid levels. 
 
TABLE 8: Correlation between CK 18M30 and other parameters in 
NASH (Pearson’s correlation). 
 Cytokeratin 18M30 
 r value p value 
BMI 0.274 0.004 
Total cholesterol 0.484 0.019 
Triglycerides 0.251 0.007 
HDL 0.201 0.002 
Fasting plasma glucose 0.334 0.003 
Uric acid 0.364 <0.001 
  
 Table 8: Pearson’ s correlation shows statistically significant positive 
correlation between cytokeratin 18M30 and BMI , total cholesterol, 
triglycerides,HDL, fasting plasma glucose and uric acid in NASH. 
 
  
Discussion 
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DISCUSSION 
 Non alcoholic fatty liver disease is the most common chronic liver 
disease  especially in the developed and industrialized countries. NASH forms 
part of thedisease which encompasses non alcoholic fatty liver (NAFL), NASH 
and NAFLD – related cirrhosis.About one fifth of patients with NASH progress 
to develop cirrhosis(115). Once cirrhosis has occurred, 45%  patients will 
develop serious complications such as variceal bleeding, ascites, and end stage 
liver failure.  The most severe end of the spectrum is  hepatocellular carcinoma.  
 
 The estimated prevalence of NAFLD is 9 - 37% of the general 
population and NASH occurs in 2% of the general population.  
 
 NAFLD is now recognized as an important component of metabolic 
syndrome, that makes an individual  more prone for atherosclerotic 
cardiovascular disease complications.  Most of the deaths in patients with the 
disease are mainly attributed to  cardiovascular disease. 
 
 Yesui et al conducted a cumulative 5 year study and concluded that, 
NASH  accounts for at least 11.3% of total cases of Hepatocellular carcinoma 
(HCC)(154). There is recent evidence that there is high incidence of HCC in type 
2 diabetics and this can beaccounted  for thehigh prevalence of NASH in these 
cases. 
 
 All patients of simple fatty liver do not progress to NASH or cirrhosis, 
and patients with NASH may  revert to simple fatty liver or even normal and 
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the severity of the degree of steatosis may  come down if the condition is 
diagnosed early and therapeutic interventions are started early. 
 
 The gold standard to diagnose NAFLD is liver biopsy.But this is an 
invasive procedure which is cumbersome, and produces many complications in 
patients.The ultrasonography is able to pick up steatosis only when there is 
more than 20% fat deposition in the liver .Transient elastography (fibroscan) 
can diagnose NASH and fibrosis, but is not easily available. 
 
 So, when the disease is diagnosed at a very initial stage using a simple 
and easily available biomarker and lipid lowering agents instituted early, the 
progress of the disease can be curtailed .  If  modification of lifestyle is also 
initiated early by starting on exercise and consuming suitable low calorie diet, 
the severity of the disease can be reduced and the most dreaded complications  
can be prevented. 
 
 This study aimed at evaluating serum levels of Cytokeratin 18 M30 as a 
noninvasive biomarker in various stages of  NAFLD.  
 
In our study we included 3 groups –                             
 Healthy Controls    - 25 
 NAFL (non alcoholic fatty liver)  - 35 
 NASH (non alcoholicsteatohepatitis) - 25 
 In this study we evaluated serum Cytokeratin 18 M30 levels using 
sandwich ELISA technique . 
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 Our study, included 25 NASH patients out of which 14 patients were 
males (56%)and 11(44%) were females, and 35 NAFL patients. Out of the 35 
NAFL patients , 18  were males (51%)  and  17 (49%) were females. 
 
 The mean age in NASH group was 49.36 (+/-10.34)   and in NAFL 
group was 58.40 (+/-8.46) .This is similar to the conclusions by Koehler 
EM(155) thatNAFLD mainly affects the middle aged and the elderly because, the 
risk factors for its development,tend to increase with advancing age .In Indian 
studies mean age was reported to be 42.90 (+/- 10.54) by RoliAgarwal(156). 
 
 The mean BMI was greatly increased in NASH and NAFL groups when 
compared to the control group.Ruhl et al concluded that prevalence of NAFLD 
increases with increase in BMI(157).Prevalence studies have proved that the 
occurrence of the disease is about 60 – 70 % obese patients and it is closely 
linked with central adiposity. 
 
 In our study the CK 18 M 30 levels were found to be significantly 
higher in the NASH group with a mean of 497.22 (+/- 173.67) IU/ L and in the 
NAFL group it was 179.84 (+/-17.45) IU/L compared to the control group 
where the mean was 76.30 (+/- 9.569) IU/l. A highly significant p value of 
<0.01was obtained. There is statistically significant difference in CK 18M30 
levels between the three groups with the highest being in NASH compared to 
NAFL and controls. . Hence,CK 18M30 levels can discriminate NASH from 
nonalcoholic fatty liver, as well as normal individuals. 
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 This is similar to the study by Feldstein et al who proved that,  CK18 
M30 levels were increased in biopsy proven NASH patients(149)  compared to 
NAFL and normal controls.   
 
 Wieckowska et al said that, CK 18 M30 levels could serve as a marker 
of hepatic inflammation. This is explained by the hepatocyte apoptosis which 
plays a key role in the pathogenesis of NAFLD and progression of NAFLD to 
NASH(158).Hepatocyte apoptosis is mediated by caspase 3 which cleaves the 
cytokeratin 18 of NAFLD patients and is released into the sera. The magnitude 
of apoptosis correlates with the degree of liver damage and fibrosis. In this 
study,CK 18 M30 levels also increased with increasing grades of fibrosis 
detected by fibroscan.So, CK 18 M30 can noninvasively grade the severity of 
NASH. Feldstein et al concluded that, For every 10 U/L increase in CK 18M30 
levels the possibility of diagnosing NASH increased by 70%(159). 
 
 In this study,the regression analysis and scatter plot shows positive 
prediction of CK 18M30 in the diagnosis of NASH and NAFL.  
 
 In this study, the ROC curve shows diagnostic performance of CK 
18M30 with a high specificity of 92.9 % and moderate sensitivity of81.8% at a 
cut off point of553.87U/L with AUROC of 0.922 (p value of<0.01) in NASH.It 
may be considered that, CK 18M30 is a highly specific and moderately 
sensitive marker in the diagnosis of NASH. 
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 Younossi et al  proved that, “ CK 18M30 is an independent predictor of 
NASH and CK 18M30 has sufficient to excellent, diagnostic accuracy, for the 
detection and exclusion of NASH in the setting of NAFLD(160)”. 
 
 Assessment of the serum levels of CK 18 M30 can be a useful 
screening, diagnostic and staging biomarker for NASH, based on this study.  
 
LIPID PROFILE 
 In this study, the total cholesterol was increased in 60% of NAFL cases 
and 84% of NASH cases ,the triglycerides was increased in 66% of NAFLand 
80% of NASH cases,and HDL was decreased in 63% of NAFL and 84% of 
NASH cases.The total cholesterol,triglycerides and HDL were increased 
compared to the control group with highly significant p value for total 
cholesterol(0.019),triglycerides(0.007) and HDL (0.002).  
 
 In this study,there was positive stastistically significant correlation 
between CK 18M30 levels and total cholesterol (r value=.484) ,triglycerides (r 
value = .251)   and   HDL ( r value = .201) .This was similar to the study by 
Miyassato et al who concluded that, there was significant correlation between 
CK 18 M30 and total cholesterol,triglycerides and HDL in NAFLD patients. 
 
 Bajaj et al proved that,subjects with NAFLD had higher levels of total 
cholesterol and serum triglycerides. Liver injury is caused by free cholesterol 
accumulation(161) .So serum lipid levels are able to predict the progression of 
NAFL and NASH. 
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 In NAFLD patients, liver produces many atherogenic factors like 
cytokines and bad lipoproteins .So fatty liver is associated with increased 
triglycerides and total cholesterol combined with decreased HDL, which pose a 
threat for the development of cardiovascular disease. Hamaguchi et al implied 
that, NAFLD plays a central role in the increased incidence of CVD(162) 
 
 Cholesterol-rich atherogenic diet induces oxidative stress and provokes 
oxidative inflammation.Mari et al gave evidence that mitochondrial loading of 
free cholesterol, but not free fatty acids sensitize the liver to TNF – α induced 
steatohepatitis(163). 
 
 Lipid lowering agents have the potential to normalize these lipid 
levels.Lifestyle modification by starting on exercise, to produce weight loss 
and control obesity is another confirmed treatment for NAFLD.Restriction on 
the intake of calories reverses hepatic insulin resistance and steatosis in animal 
models .Fasting inhibits cholesterol and fatty acid synthesis and has protective 
effect on lipid metabolism.Two drugs which can be used for obesity treatment 
are orlistat,which reduces the intestinal fat absorption and sibutramine , an 
appetite suppressant.  
 
 Inhibition of cholesterol synthesis by statins alone, or by combination 
with antioxidants like vitamin E was found to be beneficial in treating 
dyslipidemicprofile.Vitamin E supplementation suppresses the lipid 
peroxidation and TNF- α gene expression. 
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 Recent studies suggest that ezetimibe and fenofibrates inhibit intestinal 
cholesterol absorption.Dual inhibition of cholesterol absorption and synthesis 
by combined administration of ezetimibe and simvastatin is a highly 
efficacious lipid lowering strategy, and were shown to be effective and safe in 
NAFLD.  
 
FASTING PLASMA GLUCOSE LEVELS 
 In this study, the fasting plasma glucose levels was increased in  60%  of 
NAFL patients as well asNASH.The known cases of type 2 diabetes was 56% 
of NAFL patients and   67% of NASH patients.  
 
 In this study, there was a statistically positive significant correlation 
between CK 18M30 levels and fasting plasma glucose levels (r = 0.334). 
 
 Gupte.P. et al studied that NAFLD is commonly associated with type 2 
diabetes mellitus(164).Since insulin resistance is the main underlying mechanism 
in NAFLD,insulinsensitisers may be used in treatment.Thiazolidinediones 
(proglitazone and rosiglitazone) and biguanides (metformin) are insulin 
sensitisers.Thiazolidinediones are PPAR – ߛagonists.Following treatment with 
proglitazone and rosiglitazone, serum AST,ALT levels are significantly 
decreased in NAFLD. 
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URIC ACID 
 In this study, the mean uric acid was 6.87 (+/- 2.51) in NASH and 6.33 
(+/- 1.19) in NAFL, when compared to the control group  3.91 (+/- 1.26) with a 
highly significant p value of < 0.001 .This shows that uric acid levels were in 
the higher normal range in  NASH and NAFL groups . 
 
 This was similar to the findings of Yourning et al in his study, in which 
he proved that increased serum uric acid  levels in the higher normal range was 
seen in NAFLD and elevated serum uric acid is an independent risk factor for 
NAFLD.  
 
 Recent studies have proved that, uric acid is released from injured cells 
following inflammation, and in NAFLD, one of the important components of 
liver  damage is cell death which causes release and accumulation of uric acid 
in the serum.Hyperuricemia is commonly seen in metabolic syndrome and is 
positively correlated with insulin resistance. 
 
  
Conclusion 
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CONCLUSION 
 The present study was done with an aim to evaluate Cytokeratin 18M30 
as a noninvasive biomarker for non alcoholic fatty liver disease and its 
correlation with lipid profile to assess cardiovascular risk. 
 
From this study we conclude that,  
1. Cytokeratin 18M30 is a promising screening, diagnostic and staging   
biomarker for NASH. 
2. Cytokeratin 18M30 can be used as a simple, and non invasive biomarker 
instead of liver biopsy. 
3. Cytokeratin 18 M30 positively correlates with increasing grades of 
fibrosis in NASH. 
4. There is significant positive correlation of total cholesterol, triglycerides 
and high density lipoprotein with cytokeratin 18M 30. 
5. There is significant positive correlation of fasting plasma glucose with 
cytokeratin 18 M30. 
6. There is significant positive correlation between uric acid and cytokeratin 
18M30. 
7. Hypercholesterolemia and hypertriglyceridemia is associated with 
development of NAFLD. 
8. Poor glycemic control is associated with increased risk for NAFLD. 
9. Increased uric acid is an independent risk factor for NAFLD. 
  
Limitation of the study 
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LIMITATIONS OF THE STUDY 
1. This study was done without comparing with liver biopsy which is the gold 
standard for diagnosing NAFLD. 
2. The sample size for NASH is very small. 
3. There are no reference values for cytokeratin 18M30 for NAFL and NASH 
in our population. 
4. Follow up after instituting therapeutic management could not be done. 
 
  
Scope for further studies 
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SCOPE FOR FURTHER STUDIES 
 
1. Cytokeratin 18M30 can be used as a simple, non invasive biomarker in the 
management of NAFLD, after establishing the reference range. 
2. Early diagnosis of NAFLD and therapeutic intervention, can reduce 
cardiovascular risk and thus reduce morbidity. 
3. Uric acid can be used as an independent prognostic factor in NAFLD. 
4. Future studies may be undertaken to establish a correlation with insulin 
resistance, hyperlipidemia, oxidative stress and adaptive response in areas 
of research in obesity. 
5.  Studies may be conducted to establish the role of hepatic transcription 
factors and target genes in regulating lipid metabolism. 
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Annexures 
   
   
INFORMATION SHEET 
Title: Evaluation of serum Cytokeratin 18 M30 levels in cases of non 
alcoholic fatty liver disease. 
 
Investigator         : Dr. J. VINODHA, 
                              II year Postgraduate, 
                             Institute of Biochemistry, 
                             Madras Medical College, 
                             Chennai-600003. 
 
Guide                 : Prof. Dr. R.CHITHRAA, 
                            Institute of Biochemistry, 
                            Madras Medical College, 
                            Chennai-600003. 
 
The purpose of the study is to evaluate the use of Cytokeratin 18 M30 as 
a non invasive biomarker in the diagnosis non alcoholic fatty liver disease.          
          Hence, I am doing this study titled “Evaluation of serum Cytokeratin 18 
M30 levels in cases of non alcoholic fatty liver disease”, at Rajiv Gandhi Govt. 
General Hospital, Chennai. For this study I need 5mL of blood from 60 non 
alcoholic fatty liver disease patients and 30 apparently healthy individuals.  
          Your identity will be kept confidential throughout the study as well as 
during publication or presentation of the study findings in any clinical forum or 
journals. Participation in this study is purely voluntary. You can withdraw from 
this study at any time. Your decision will not result in any loss of benefits to 
which you are entitled. The results of the study will be intimated to you. If you 
have willingness to participate in this study, kindly sign in this information 
sheet and the consent form. 
 
 
Signature of the investigator                                Signature of the participant 
                                                                              Thumb impression 
Place: 
Date:      
                                   
PATIENT CONSENT FORM 
Title of the study :"Evaluation of serum Cytokeratin 18 M30 levels in cases 
of non alcoholic fatty liver disease."  
Name :                           Date : 
Age :        OP No: 
Sex :        Project Patient No : 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or 
it has been read to me). I felt free to ask questions about the study which were 
answered. I, hereby, give my consent to be included as a participant in 
“Evaluation of serum Cytokeratin 18 M30 levels in cases of non alcoholic 
fatty liver disease.” 
1. I have read and understood this consent form and the information that was 
provided. 
2. I have had the consent document explained. 
3. I have been explained the nature of the study. 
4. I have been explained about my rights and responsibilities by the 
investigator.  
5. I have informed the investigator of all the treatments I am taking or have 
taken for the past -- months/years including any native (alternative) 
treatment. 
6. I have been informed about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms. 
8. I have not participated in any research study within the past ________ 
month(s). 
9. I am aware of the fact that I can opt out of the study at any time without 
having to give my reason and this will not affect my future treatment in this 
hospital. 
10. I am aware that the investigator may terminate my participation in the study 
at any time, for any reason, without my consent. 
11. I hereby give permission to the investigator to release the information 
obtained from me as a result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
out of the interest of the public. 
12. I have understood that my identity will be kept confidential even if my data 
are published. 
13. I have had my questions answered to my satisfaction. 
14. I have decided to be a participant in the research study. 
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form, I attest that the information given in 
this document has been clearly explained. I have understood the contents of the 
consent form and, I will be given a copy of this document. 
For participants: 
Name and signature / thumb impression of the participant (or legal 
representative, if participant  incompetent/For age 10-17 yrs-Name& signature 
of the parent/guardian.) 
Name ____________________________ Signature with date_______________ 
  
Name and Signature of impartial witness (required for illiterate patients): 
Name ____________________________ Signature with date_______________ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
Name ___________________                    Signature with Date_____________  
   
 
 
                                           PROFORMA 
 
Date :        Sample Id :  _____________ 
Name :    Age :   Sex :  Ht (cm):  Wt (kg) : 
                                                                                             Waist circumference:  
Pre/Post Menopausal: 
Ethnicity:    Community :    
Duration of Symptoms/diseases :  
Treatment history : 
H/O alcohol intake in the last five years:   
H/O jaundice 
H/O previous surgeries    
Other autoimmune diseases : ___________________   if any duration ________________ 
Associated diseases with duration : 
Type 2 Diabetes Mellitus                 Hypertension                  Ischemic heart disease                                                                 
Congenital liver diseases    
Hypothyrodism                    PCOD                                     Hypercholesterolemia        
Gastric surgeries                      Inflammatory bowel disease                                                                      
Others       
Drug Intake: 
 Steroids                      Acetaminophen        Tetracyclines       
 Any other medications              Smoking        Passive smoking       
 Alternative medicine intake     
Clinical History: 
H/O upper abdominal pain    __________ 
H/O nausea or vomiting         __________   
H/O loss of appetite               __________ 
H/O recent jaundice    _____ 
H/O breathlessness      ______ 
H/o weight gain           _______ 
H/O recent  surgeries    ______ 
 
O/E :  
Pallor ____    Icterus  ______        Lymphadenopathy  ______ 
 Pulse :                   B.P     :                     Temp: 
CVS/RS : 
P/A : 
Sample collection     : 
Date ________________                   Time   ______________ 
Sample analysis         : 
Date  ___________________ 
 
Investigations: 
Serum cytokeratin 18 M30  : 
Serum fasting lipid profile   : 
Plasma Fasting blood glucose: 
Serum liver function tests : 
Serum uric acid : 
 
